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Type one diabetes mellitus (T1DM) is one of the most common, serious chronic diseases of 
childhood. Hyperglycaemia causes well known micro- and macro- vascular complications. 
Less well explored are the ways the gastrointestinal (GI) system is affected. This research 
aimed to examine in depth three aspects of the gastrointestinal manifestations of T1DM. 
Coeliac Disease  
Coeliac Disease (CD) occurs more frequently in children with T1DM, the two diseases share 
genetic and environmental risk factors.  To establish how clinicians in New Zealand screen 
for and manage CD in T1DM, a benchmark survey was performed. All paediatricians caring 
for children with T1DM in NZ were sent an online questionnaire with multi-choice and open 
questions regarding their individual practice.   
Ninety-two percent of the clinicians replied. Most screen for coeliac disease in T1DM but 
approximately a third do not. Those that do not screen use poor control, poor growth and GI 
symptoms as a trigger for testing. All were sensitive to the burden of the double diagnosis. 
Gastric emptying 
Gastric emptying has been demonstrated to be delayed in adults with T1DM, which has 
potential adverse effects on blood sugar control and symptomatology. Evidence regarding 
the rate of gastric emptying in children with T1DM is conflicting and inconclusive. This pilot 
study aimed to investigate gastric emptying in children with T1DM and in health. Gastric 
emptying was measured using Carbon 13 (C13) breath testing, a non-invasive, very low risk 
procedure. 
Nineteen cases and 15 age and sex matched controls underwent testing.  The mean gastric 
emptying coefficient [mean (95% CI)] in cases was higher than in controls, indicating a 
shorter gastric emptying time (3.19 (2.97 – 3.41) vs 2.90 (2.74 - 3.10), p = 0.03). Mean 
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GET1/2 [mean (95% CI)] was not different between the two groups (cases 99 (68 - 128) mins 
vs 103 (88-118) mins, p = 0.8).  
Secondary analysis suggested that there was a relationship between the duration of T1DM 
and the speed of gastric emptying but numbers were small and the result did not meet 
statistical significance.  
Gastrointestinal symptoms: 
Anecdotally children with T1DM are said to complain of more GI symptoms than their 
healthy peers.  We aimed to prospectively establish the frequency and intensity of GI 
symptoms in a clinic population of New Zealand children with T1DM compared to an aged-
matched group of healthy children. Caregivers were given a 10 item questionnaire about 
their child’s experience of GI symptoms in the previous month.  Responses were marked on 
a Likert scale, from 0 (not at all) to 4 (a whole lot). Participant’s scores for each question 
were also summed together to give an overall score as a marker of the overall intensity of 
symptoms. 
Two hundred and forty four children completed the questionnaire. Cases and controls had 
similar rates of any GI symptoms (80% of controls v 85% cases, OR 1.5 (95% CI: 0.7-3.1)). 
Children with T1DM had higher mean scores for abdominal pain (1.3 v 1.0, p = 0.02) and 
reflux (0.4 v 0.20, p = 0.02). The overall mean score was also higher in cases (4.9 v 3.4, p = 
0.02) indicating the intensity of their complaints was higher than healthy controls.  
Conclusion: 
This thesis shows the importance of the gastrointestinal manifestations of T1DM in children. 
Further research to expand upon our knowledge of these manifestations will allow for 
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 Chapter One: Introduction 
Autoimmune Type one diabetes mellitus (T1DM) is one of the most common chronic 
diseases in childhood (1).  Destruction of the pancreatic islet cells results in an absence 
of circulating endogenous insulin (2). Glucose cannot be utilised by cells, resulting in 
hyperglycaemia and intra cellular starvation (2). Exogenous insulin injections allow for 
survival but so far cannot replicate a smooth physiological homeostasis of blood glucose 
levels, with most patients spending at least part of the day out of the physiological range 
(3). The resulting hyperglycaemia causes well-documented complications, involving the 
eye, kidney, heart and brain, as well as peripheral nerve damage (4-7).   
Often mentioned by clinicians, but not as well documented in the literature, are effects 
on the gastrointestinal (GI) system. The gut is intrinsically involved in the delivery of the 
components of food to the blood stream and in turn its mechanism of action is affected 
by the blood glucose level (8). Coeliac disease (CD) occurs more commonly in children 
with T1DM (9), the two disease states have common genetic predispositions and 
hypothesised causal mechanisms, which raises the question of the utility of screening 
(10). The rate of gastric emptying is known to be altered in T1DM (11). Children with 
T1DM have reason to complain more of GI symptoms, and anecdotally do. 
This thesis aims to explore the gastrointestinal manifestations of T1DM with particular 
reference to CD, GI symptoms and gastric emptying.  
1.1 Diabetes mellitus type one 
1.1.1 Definition 
Diabetes mellitus is diagnosed when an individual’s blood glucose is persistently 
elevated in the presence of hyperglycaemic symptoms. The current consensus is a 
fasting blood glucose of ≥ 7.0 mmol, or a random blood glucose of ≥ 11.1 mmol in a 
patient with classic symptoms of hyperglycaemia or a blood glucose of greater than 11.5 
mmol during a standardised oral glucose tolerance test(12). Diabetes mellitus is 
classified as “Type one” when there is an absence of circulating insulin and can be 
further classified either as autoimmune, with evidence of autoimmunity to the 
pancreatic beta cells, or less commonly idiopathic, when there are no diabetes-
associated autoantibodies detectable in the blood (2). 
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1.1.2 Epidemiology of T1DM 
The International Diabetes Federation (13) estimates that approximately 500,000 
children are living with T1DM worldwide.  
 The International Diabetes Federation has published worldwide incidence rate 
estimates. However, prevalence and incidence rates vary in different geographical areas 
around the world. The estimated rates are highest in developed European and Northern 
American countries but estimated rates in New Zealand and Australia are almost as high 
(13, 14) (Figure 1.1).  
 
Figure 1.1: Estimated new cases of T1DM (<15yrs) per 100,000 children per year, 2015, 
used with permission IDF (13) 
 
Most epidemiological data in New Zealand has been collected from Auckland or 
Canterbury populations and the overall trend is to increasing numbers of children 
diagnosed and living with T1DM.   
A New Zealand wide, prospective case reporting study found an annual incidence of 
17.9/100,000 in children 0-14 years old during 1999-2000 (15).  A more recent estimate 
comes from a report from a national “virtual register” collected from DHB records, 
which reported 1103 children younger than 15 living with T1DM in 2011, giving a 
nationwide prevalence of 127/100,000 (16).  
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Regional studies within New Zealand have also demonstrated increasing incidence and 
prevalence rates. Examination of a comprehensive database of children with T1DM in 
the Auckland region showed that incidence rates had increased over time. In 2009, the 
Auckland regional incidence of T1DM was reported as 22.5/100000 in children younger 
than 15 years old compared to 10.9 per 100,000 in 1990, (p <0.0001) (17) (Figure 1.2). 
A Canterbury study showed an incidence of 28.6/100,000 in 2004, the highest since 
1970, although significant year-to-year variation over the 20 years of data collection 
should be noted (18).  
 
Figure 1.2: Change in incidence over time in Auckland children. From Derraik (17). 
 
A prevalence study in Canterbury youth found a prevalence of 443/100000 in 15 – 19 
year olds in 2010 (19). This represented a 20% rise in absolute numbers from a study 
seven years earlier, which reported prevalence rates of 369/100000 (20), however the 
increase did not meet statistical significance (19).  
Although the exact numbers vary, and have varied over time, the lowest reported 
prevalence rate predicts that approximately 1/500 school children in NZ have a 
diagnosis of T1DM (13). This represents a significant burden of disease both in terms of 
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numbers of children living with a chronic illness and in monetary value as it has been 
estimated that each person with T1DM in NZ requires a healthcare spend of 
approximately 4962 US dollars per person per year (13).  
1.1.3 Pathophysiology 
The underlying deficit in T1DM is insulin deficiency due to endocrine pancreatic failure, 
however the exact process that leads to this is an area that has generated much 
investigation. In autoimmune T1DM, it is clear that there is a complex interaction of 
genetic and environmental factors that eventually leads to autoimmune destruction of 
the insulin secreting islet cells of the pancreas. 
The autoimmunity is evidenced by antibodies directed against the beta cells. Ninety 
percent of newly diagnosed individuals with T1DM have at least one of either: auto 
antibodies to insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma-associated 
autoantigen 2 (IA2A), and/or zinc transporter 8 (ZnT8A) (21). A cohort study with 20 
years of follow up has demonstrated that antibodies may precede the development of 
clinical diabetes by many years, however the presence of the antibodies does not 
necessarily mean that the disease state will follow (22).  
1.1.4 Genetics 
There is a clear familial predisposition to developing T1DM. First-degree relatives have 
a 1-15% chance of developing T1DM compared to 0.1% risk in the general North 
American population, while identical twins have a 23-50% lifetime risk (23, 24).  
The biggest genetic susceptibility appears to come from the major histocompatibility 
complex (MHC) on chromosome 6 (25). The MHC includes the genetic code for Human 
Leucocyte Antigens (HLA), cell surface glycoproteins that are involved in antigen 
presentation to T cells. There are two classes of HLA.  Class II HLA are mostly expressed 
on B lymphocytes, dendritic cells, macrophages and activated T lymphocytes, they are 
recognised by CD4 helper/inducer T cells (23). Polymorphisms of these class II HLA are 
linked to T1DM. Changes in the structure of the HLA alter autoantigen binding and are 
thought to increase and decrease susceptibility to T1DM (26, 27). 
Two specific HLA polymorphisms are found in 90% of patients with T1DM: HLA-
DR3,DQB1*0201(also known as DR3-DQ2) and/or HLA-DR4,DQB1*0302 (also known as 
DR4-DQ8). This carriage rate is more than double that of controls with either haplotype, 
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who have been demonstrated to have carriage rates of around 40% (28). Carrying both 
versions of the allele confers the biggest risk. For example, a population in Denver with a 
high proportion of DR3-DQ2 and DR4-DQ8 carriage rates, found that children with both 
alleles had a 5% chance of developing T1DM compared to 0.3% in the general 
population (29, 30). 
HLA genes are inherited in an autosomal fashion, but as the incomplete concordance of 
the diabetes phenotype in carriers of the at-risk HLA genes demonstrates, T1DM is a 
polygenic condition. At least 40 other loci have been identified as involved in T1DM risk 
(23). Genes that have generated interest include, the insulin gene on chromosome 11 
and genes that are involved in antigen presentation, CTLA4, PTPN22 and Cd25 (23). 
Several other genes are of interest: some of these loci are common to CD and T1DM (31).  
1.1.5 Environmental factors 
Whilst most children with T1DM carry at least one HLA gene that confers risk, most 
children who carry the risk genes do not develop diabetes, and 80% of cases of T1DM do 
not occur in individuals with an affected family member (25). This degree of variability 
suggests that environmental factors must impact on the expression of the genetic 
information that then results in the T1DM phenotype. 
As discussed earlier, incidence studies have repeatedly shown that the incidence of 
T1DM is rapidly on the rise (3, 13).  This change is too rapid to be attributable to genetic 
changes and suggests that environmental factors play a significant role in the 
development of T1DM. A proposed a model for how T1DM develops is that  while a 
genetic susceptibility is key, environmental factors are probably important throughout 
the entire natural history of the disease(3). Proposed environmental factors include, 
viruses, diet and the interplay of the gut microbiota and exposure to antigens. 
Investigating the potential role viruses may play has been a major area of attention, 
particularly enterovirus and norovirus.  These common pathogens are postulated to 
either directly infect the pancreas and cause destruction or trigger autoimmunity. 
Viruses have been demonstrated in animal models and humans to cause lymphopenia 
(32) and have been found in pancreatic cells (33-35). Norovirus is one of the four most 
common pathogens found in an observational study of genetically at risk toddlers, 
although an association with disease has yet to be demonstrated (36).  
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Another area of intense focus has been diet. Longitudinal cohort studies - such as the 
Diabetes Auto Immunity Study in the Young (DAISY) (37), Babydiet (38) and The 
Environmental Determinants of Diabetes in the Young (TEDDY) (39) have followed 
children at risk of T1DM and examined many environmental and anthropometric data. 
Areas of interest include breastfeeding, introduction of solids, dietary glucose, cow’s 
milk intake and introduction of gluten. No single food has been shown to “cause” T1DM 
although the research has given rise to recommendations: 4-5 months of age is safe for 
the introduction of solids (37), gluten exposure is not related to the development of 
T1DM (40, 41) and that breastfeeding maybe protective (42). Reducing exposure to 
cow’s milk protein in infancy initially looked promising, but an intervention study, with 
7 years of follow up has not demonstrated a change in incidence (43).  
Vitamin D has also been of interest; a large cohort study in Finnish children did show an 
association between vitamin D supplementation and lower rates of T1DM (44). However 
no association was found between measured vitamin D levels and the risk of T1DM in 
another study (45).  
Individuals with T1DM show greater levels of certain bacteria compared to healthy 
controls (46-48). Animal models have shown that exposure to certain bacteria is 
protective against the development of diabetes in non-obese diabetic (NOD) and 
biobreeding diabetes-prone mice (48). Other investigators have demonstrated that 
when a strain of bacteria capable of disrupting intestinal barrier function was 
introduced to NOD mice the rate of progression to insulinitis increased (49). 
Many of the postulated mechanisms for the development of T1DM could potentially 
mediate their effect via the gut. Food is obviously digested in the gut, enterovirus and 
norovirus are gut pathogens. Certain patterns of gut microbiota are associated with 
T1DM, it is postulated that strains of flora are associated with pro inflammatory 
environments, leading to the introduction of antigens to the submucosa and the 




1.2 Coeliac Disease 
1.2.1 Definition 
CD is the most widely recognised and commonly seen co-morbid GI condition seen in 
T1DM. 
CD is a chronic enteropathy of the small bowel. In genetically predisposed individuals, 
exposure to dietary gluten causes an immune response in the villi of the small bowel, the 
ongoing villous atrophy and crypt hyperplasia lead to nutrient malabsorption (50). It 
can be classified as classical, non-classical and the increasingly recognized subclinical, 
which is defined as evidence of autoimmunity with no or few clinical findings or 
symptoms (51). 
The disease is typically diagnosed by finding evidence of autoimmunity to either gluten 
or an enzyme involved in the digestion of gluten, tissue trans-glutaminase (TTG) (50). A 
biopsy to confirm small bowel inflammation has generally been gold standard for 
diagnosis, and remains so for the population of children with T1DM (50).  
1.2.2 Epidemiology 
It is commonly accepted that CD occurs in the general population with a prevalence rate 
of around 1% (52). There is significant geographical variation, with community 
prevalence ranging from 0.3% in Germany, to > 2% in Finland (53). A population based 
screening study in Christchurch, New Zealand in the 1990s indicated that the prevalence 
rate of CD was 1.2% in Canterbury adults (54). Recent work retrospectively reviewing 
the paediatric population of Canterbury could not make prevalence estimates but found 
a rate of diagnosis of 32 biopsy proven cases per year, a rate that had increased from 13 
per year over an 11-year period (55). A New Zealand cohort study found a prevalence of 
1% in New Zealand children, although they were relying on parental report (56). 
Studies from around the world have repeatedly shown that CD occurs more commonly 
in people with T1DM than in the general population. Prevalence rates vary from 1.6% 
(57) to 16.4% (58). There is a large range of definitions and methodologies in the 
numerous studies.  A comprehensive meta-analysis of only longitudinal studies with 
robust methodology found a quality-weighted prevalence of 5.1% (CI 3.1-7.4%) in the 
European and Australian populations included in their review (9).  
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Pham Short et al. (9) also reported incidence rates showing that 40% of cases of CD 
diagnosed in T1DM are diagnosed in the first year of T1DM diagnosis and 79% are found 
within 5 years. 
1.2.3 Pathophysiology 
CD is an immune mediated condition. A strong underlying genetic basis has been 
recognised for many years, but environmental factors are also important in the 
pathogenesis. 
1.2.4 Genetics 
Like T1DM, CD is far more common in individuals with certain HLA subtypes. Ninety to 
ninety-five per cent of individuals with CD are positive for the HLA molecule DQ2.5, 
which is encoded by the genes HLA.DQA1*5.01 and HLA.DQB1*2.01, almost all other 
cases are either HLA DQ8 or DQ 2.2 (59-61). As in T1DM these genotypes do not pre-
determine disease expression, but are necessary to be present for the disease to 
manifest. (These high-risk HLA subtypes, HLA-DQ2 and HLA-DQ8, are the same as those 
that put an individual at risk of developing T1DM.) It is thought that the molecular 
structure of these higher risk HLA molecules allow for enhanced binding of CD4 T-cells 
in the small bowel mucosa to de-aminated gliadin molecules, a product of the digestion 
of gluten (59).  
Variations in HLA subtype are not adequate to explain the immune processes observed 
in CD and much effort has been spent identifying other genes involved in the 
pathogenesis. As technology to map the genome and search for genes associated with 
disease have advanced, the areas of genetic code suspected to be associated with 
autoimmune disease have increased in number. The TEDDY group has recently 
published work examining the HLA associated regions (62) as well as non- HLA (63) 
associated with CD. Many areas that have been identified add weight to the immune 
mediated model of CD as they are involved in cell selection, regulation, survival and 
stimulation of T-cells (61, 64). 
Genetic discoveries have led to a hypothesis that helps explain the relationship between 
CD and T1DM.  The immune mediated inflammatory process driven by CD autoimmunity 
results in impaired intestinal barrier function (64), which allows the introduction of 
environmental factors to the submucosa which may then lead to the autoimmune 
process which results in the development of T1DM. 
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1.2.5 Environmental factors 
As in T1DM, whilst there is no doubt that there is a genetic risk, the lack of complete 
concordance in twin and family studies strongly suggests that environmental factors 
play a role in the development of CD (65).  
The most obvious factor is gluten. CD is more common in areas where gluten is 
consumed heavily and barely recordable in geographic areas where gluten is not 
ingested in large amounts (61). 
This dietary link has lead researchers to look at the timing of introduction of gluten as a 
potentially modifiable risk factor. Observational work from Sweden where a change in 
infant feeding advice coincided with increasing incidence of CD made this hypothesis 
seem more likely (66). However, prospective observation studies did not show this (67, 
68) and two randomised controlled trials also failed to show any change in incidence 
with delaying or advancing the introduction of gluten to breast fed or formula fed 
infants (69, 70). The most recent work suggests that the timing of gluten introduction 
does not impact on subsequent risk of CD (71). 
Observational work has also been done to see if any perinatal factors affect the 
subsequent risk of CD. The most convincing factor is elective caesarean-section, which 
was associated with a small increase in OR 1.15 (1.04-1.26), a hypothesis to explain this 
is variation in the microbiota due to the lack of exposure to the flora in the birth canal 
(72). 
As with T1DM the role that viral infection may play in triggering autoimmunity has been 
investigated, although results have not been conclusive. One prospective study following 
children with high risk HLA subtypes did show that there was a trend to increasing risk 
with increasing occurrence of rotavirus infection, but this was not significant at each 
individual time point and the occurrence of infection was only inferred from serological 
changes (73). The role of gastrointestinal infection is also supported by work that has 
shown increased prevalence of CD in children born in summer months (74). One 
hypothesis mooted to explain this finding is that these children are introduced to solids 
at a time when gastrointestinal infections are at their peak.  
Taking the viral work a step further than inference, a group has identified a subset of 
anti-TTG antibodies that recognise rotaviral proteins. The presence of these anti-
rotaviral antibodies was far more common in children with CD, but were not exclusively 
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found in the disease state. Further molecular work demonstrated that the antibody did 
modify the expression of genes involved in CD pathogenesis, for example genes that 
alter epithelial function (75). 
Again, similar to the body of work in T1DM, the intestinal microbiota in individuals with 
CD has been investigated, as was well summarised in a recent review (76). The 
microbiota in individuals with CD and those in the normal population does differ, but no 
“typical” CD microbiota has been found. The changes include a decrease in protective 
bacteria and an increase in the amounts of bacteria thought to favour a pro-
inflammatory state. A hypothesis to explain an observed peak in incidence in Sweden 
was that the changes in dietary practise could be changing the microbiota, by selecting 
for bacteria that favoured those dietary changes. As summarised earlier, the suggested 
dietary changes however have not been consistently linked to CD (67, 68). It has also not 
been established which came first, the pro-CD microbiota or if the pathophysiology of 
CD promotes certain bacteria.  
1.2.6 Similarities between the pathogenesis of DM and CD 
There are many parallels between the pathogenesis of CD and T1DM. Much of the 
research has followed similar avenues: genetic, viral and the interplay of the intestinal 
microbiome and autoimmunity. 
An animal model demonstrated a link between a gluten containing diet and the 
development of hyperglycaemia. NOD mice fed a GFD from birth had a different faecal 
microbiota and a reduced rate of hyperglycaemia, which reversed when gluten was 
introduced (77). 
The interplay between the immune system and the gut microbiota offers an explanation 
for some of the increase in CD seen in T1DM. There are probably several factors at work, 
obvious shared genetic susceptibility, mediated through altered immune function, 
shared environmental risk factors and almost certainly impaired gut intestinal barrier 
function that allows the exposure of antigens to immune cells and the subsequent 
development of autoimmunity to gluten and or insulin 
The close relationship becomes important clinically when considering the question of 
screening in T1DM for CD, as it may have important implications for growth, diabetes 
control and quality of life. It is also of importance when thinking of primary prevention 
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of both illnesses, as perhaps there is some environmental modification that could be 
made to prevent the development of the disease state. 
1.3 Gastric emptying in T1DM 
Gastric emptying is complex; many factors influence the rate that food is emptied from 
the stomach. There is a substantial body of evidence in the adult literature and growing 
in paediatrics, that gastric emptying is altered in T1DM. Many physiological factors that 
are impacted by the pathology of T1DM are related to the complex neuronal and 
hormonal control of gastric emptying. Knowledge of gastric emptying rates is important 
as altered gastric emptying may be associated with GI symptoms(8). In T1DM the rate of 
gastric emptying is of even more relevance as the rate that the stomach empties is linked 
to the delivery of food and therefore glucose to the rest of the digestive system, which 
can impact on blood glucose levels(78). 
1.3.1 Physiology of gastric emptying 
Gastric emptying is the rate that food leaves the stomach. The way that food is broken 
down and then allowed through the pylorus is essentially a function of the motor 
activity of the three parts of the stomach – the proximal stomach, the antrum and the 
pylorus - as well as the proximal intestine (8).  
While fasting, the stomach goes through 3 phases of contractions, which together are 
called the “migrating motor complex” (79). When food is ingested this resting pattern 
changes to a post-prandial pattern of irregular contractions. The stomach must relax to 
allow the food into the proximal stomach where it is stored, before it moves into the 
antrum to be ground up into tiny particles, then emptied incrementally through the 
antrum (8).  
The rate that the stomach empties alters according to the make-up of the meal. The 
calorie value, fibre content and texture of a meal determine the emptying speed (8). 
Liquids with no calorie value empty exponentially, liquids with more calorie value 
empty in a more linear fashion and solids are emptied last, as they need to be churned 
before they can be emptied (8). The phase of a meal where the solids are retained is 




Coordinated relaxation and contraction of the three parts of the stomach is under both 
neural and hormonal control (79). The enteric nervous system, which has plexi in the 
sub mucosal and myenteric layers of the stomach, along with the autonomic nervous 
system, which also innervate the gastric wall, are involved in the coordination of muscle 
contractions (80).  
The interstitial cells of cajal (ICC) are ‘pacemaker” cells which produce the electrical 
signals that drive the maximum contraction rate of the stomach (80). Once food arrives 
in the small intestine, inhibitory pathways work to reinforce motor activity that slows 
gastric emptying, by relaxing the antrum and fundus but strengthening the pyloric 
contractions (79). The rate of gastric emptying usually varies between 1-4 kcal/min 
(79). Gastric emptying activity is mediated directly by the vagus nerve as well as 
hormones secreted by the gut: Glucagon-like peptide – 1(GLP-1), cholecystokinin, 
peptide YY and amylin (also called human islet amyloid peptide), which is co-secreted 
with insulin (81). 
1.3.2 Gastric emptying in T1DM 
It has been recognised since at least 1958 that gastric emptying is altered in adults with 
diabetes (11).  
Diabetic gastroparesis is a clinical syndrome where there is a symptomatic delay in 
gastric emptying, in the absence of physical obstruction and in the presence of 
euglycaemia (82). How many adults with T1DM are affected by gastroparesis is not 
clear, as definitions have varied and achieving euglycaemia during testing is not easily 
accomplished (81). Prevalence in some tertiary centres has been reported as 40%, but 
community estimates put it closer to 5% in T1DM, and under 0.5% of controls (83). 
Gastroparesis is not the only abnormality of gastric emptying demonstrated in diabetes 
mellitus. A retrospective case review of 129 patients with diabetes mellitus (about 50% 
had T1DM) who had scintography performed for various clinical indications showed 
that while 36% of the patients had delayed gastric emptying, 22% had rapid gastric 
emptying. The study aimed to establish a diabetes “phenotype” of symptoms, however 
the only predictor of accelerated gastric emptying was neuropathy (OR, 3·60, 95% CI, 
1·007–12·89) and weight loss for delayed gastric emptying (OR, 2·81, 95% CI, 1·09–
7·23). Insulin therapy was associated with a lower risk for rapid GE (OR, 0·08; 95% CI, 
0·01–0·53) but otherwise no other indicators of control or duration of diabetes were 
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useful to discriminate if gastric emptying would be abnormal. The applicability of this 
study to paediatric clinical practice and children with T1DM is hampered by the patient 
group – adults, nearly 96% who had GI symptoms at inclusion in the study (84). 
A study with small numbers, but interesting findings about gastric emptying in different 
physiological states, performed scintography under varying conditions in 15 patients 
with T1DM and 10 matched controls (85). Patients were shown to have faster gastric 
emptying that controls 90–120 mins post meal (p = 0.03). This finding became more 
pronounced when the controls were kept hyperglycaemic; they had a marked slowing of 
their gastric emptying, which was not seen in cases. The groups were then given 
pramilinitide (an amylin analogue) and the T1DM patients’ gastric emptying then 
slowed to match that of controls. It was not clear what the duration of T1DM was in the 
patients, but they were well selected to have no signs of autonomic dysfunction. 
Gastric emptying has also been demonstrated to be accelerated in T2DM. Two 
scintography studies with small groups of patients demonstrated accelerated gastric 
emptying (86, 87). Both of the studies were in patients with relatively newly diagnosed 
T2DM, with few complications perhaps indicating that gastric emptying itself was a 
factor in the hyperglycaemia seen clinically. 
1.3.3 Gastric Emptying in children with T1DM 
All of the above studies were performed in adults with diabetes. Some studies have been 
done to evaluate gastric emptying in children and young people with T1DM. The 
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The studies have used various methods to measure gastric emptying. There is no 
unifying agreement on what constitutes delayed or rapid gastric emptying, so simple 
comparison or meta-analysis is not possible. The two with possibly the most robust 
method of measurement – scintography – show no difference in the rate of gastric 
emptying between cases and controls (91, 92), although in both, the cases had a 
tendency to a longer GE time. All of the other studies did show differences in gastric 
emptying rates between cases and controls (88-90, 93-95).  
Most of the studies tried to look for factors hypothesised to be associated with altered 
gastric emptying.  None of the children who had investigations performed had evidence 
of autonomic dysfunction. Most of the studies used HbA1c to measure control and none 
demonstrated a difference in gastric emptying that could be related to this marker.  
When recorded the duration of diabetes did not seem to impact on results.  
Drawing overall conclusions from this body of research is difficult due to the 
heterogenicity of the studies. Also numbers in each study were relatively small, 
indicative of the difficulty performing invasive and time consuming test on children. 
Despite the current body of evidence, it is not clear what the pattern of gastric emptying 
is in children with T1DM. 
1.3.4 Pathophysiology of gastric emptying differences 
Most of what is known about the pathophysiology of gastric emptying differences in 
T1DM comes from adult studies. As discussed above, gastric emptying is influenced by 
many factors. Hyper and hypoglycaemia certainly play a role in reversible alterations.  
The mechanisms that explain pathologically altered gastric emptying in T1DM include 
alterations in the gastric hormones, signalling peptides and changes in Nitric oxide 
levels (96).  Cell damage to the smooth muscle layer and reduced numbers of ICC, have 
been demonstrated (97, 98). Neuronal changes also probably play a part, particularly 
damage to the vagal nerve (99).  
Understanding the changes in gastric motility provoked by the hyper- and 
hypoglycaemia that occur with eating are important when considering gastric emptying, 
particularly in T1DM, when it is likely there will be marked changes in the blood glucose 
after ingestion of a meal. Elevated blood glucose results in a reduction in the speed of 
gastric emptying (100). Acute changes are seen in the muscle activity of the stomach – 
the fundus and antrum relax while the pyloric contractions are attenuated (79). 
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Hypoglycaemia in contrast results in a marked increase in gastric emptying (101). These 
changes are still seen within the physiological range (102).  
It has not been fully established exactly how physiological or pathological changes in 
gastric emptying are mediated – gastric emptying is a complex process and therefore it 
can be expected that many factors are involved. Interest has focused on hormonal 
changes, where there is potential to use pharmacological methods to alter gastric 
emptying (96). The figure adapted from Marathe et al.(103) summarises some of the 
feedback loops at play when there are changes in blood glucose.  
 
Figure 1.3: The inter-relationship of gastric emptying, incretin hormones and post-prandial blood 
glucose. Glucagon like protein-1 (GLP-1), glucose dependent insulinotrophic peptide (GIP), adapted 
from Marathe (103).  
 
Amylin (islet amyloid polypeptide) a hormone co-secreted with insulin from the beta 
cells of the pancreas is likely to be involved (8). Release of amylin results in slowing of 
the gastric emptying rate (102). Reduced levels of amylin have been consistently seen in 
children with T1DM (104-106). Heptulla et al. (106) demonstrated that this reduction in 
amylin was associated with slower gastric emptying, contrary to her hypothesis that it 
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would accelerate gastric emptying, and possibly illustrating the complexity of gastric 
emptying and successfully measuring it. 
Grehlin is another hormone that has effects on gastric motility. It is synthesised in the 
gut and has receptors throughout the body (8). One of grehlin’s actions is to accelerate 
gastric emptying (107). Elevated levels of grehlin have been found in children with 
T1DM (104, 108).  
Other peptides released by the gut, such as GLP-1 and glucose-dependent 
insulinoptrophic peptide(GIP) are released by the intestine when in contact with food 
and these also work to slow gastric emptying (103).  
While it has been demonstrated that gastric emptying is altered by the level of glucose in 
the blood, the rate that glucose is delivered to the gut for absorption also affects the 
blood glucose.  A group in Australia have shown that alterations in gastric emptying 
accounts for up to 30% of the variability in blood glucose in health (109). 
Post-prandial blood glucose has been a focus of research as the typical rise in blood 
glucose after a meal is a significant contributor to over-all diabetes control (78, 103). 
Monnier (110) showed that the contribution of post-prandial blood glucose was 
between 30-70% of the overall time an individual was hyperglycaemic, when they 
analysed diurnal blood glucose in a group of 240 people with T2DM. Post-prandial blood 
glucose had the biggest impact on over-all area under the curve in those with the highest 
average HbA1c (110).  
There is also a body of evidence that suggests that much of the oxidative damage to 
nerves and vessels that result in the long term complications of T1DM is caused by the 
post prandial fluctuations in blood glucose (111).  
How control of T1DM in turn affects gastric emptying is not straightforward as so many 
factors impact on overall control, and a clear relationship has not been found (112). The 
landmark cohort study that determined that tight blood glucose control resulted in 
better outcomes, the Diabetes Control and Complications Trial (DCCT) (113), was 
continued as the Epidemiology of Diabetes Interventions and Complications (EDIC) 
study, this group evaluated gastric emptying in a cohort of 78 cases. At year 20 since 
entry into the study, 50% had normal gastric emptying, 47% had delayed and 3% had 
rapid gastric emptying. Those with delayed gastric emptying had higher HbA1c at the 
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time of testing, a higher average HbA1c over the year and there was also an association 
with severe nephropathy and higher upper GI symptom score (114).  
1.3.5 Relevance of Gastric emptying in clinical practise 
Because of this inter woven relationship of gastric emptying and glycaemic control, the 
more we understand about the mechanisms of gastric emptying the better our 
understanding of blood glucose control. Given that peaks of blood glucose are times 
when oxidative damage is done, interventions that aim to smooth these peaks would 
appear to be of benefit to patients (78). Before interventions can take place there is still 
more to be learnt about the pathophysiology of gastric emptying. 
1.4 Measurement of gastric emptying  
1.4.1 Development of the Carbon 13 oral breath test 
The generally accepted gold standard to measure gastric emptying is scintography.  The 
subject ingests a meal labelled with a radioactive marker, usually technetium and a 
gamma camera is used to measure the removal of the trace from the stomach.  This 
necessitates a dose of radioactivity, time in front of the camera, cooperation of the 
subject and expensive machinery.  For many reasons this test has not been deemed 
desirable or accessible for research studies in children (115).  In the 1990s 
investigators, chiefly at Leuven in Belgium and the Mayo clinic in the United States 
began to develop a new method of measuring gastric emptying using isotopes of carbon. 
Test subjects are fed a meal rich in carbon 13 (C13), a stable isotope.  Samples of their 
breath are then captured over a certain period of time.  The breath is analysed by mass 
spectrometry and the amount of carbon dioxide (CO2) rich in C13 (13-CO2) excreted over 
time can be measured. Two curves are produced: one describing the measured 13-CO2 
recovered in the breath, the percentage of excretion per hour of the total C13 dose, (see 
figure 1.4) the other is the percentage the total C13 dose excreted in the breath over time 
(see figure 1.5). Four parameters are generally calculated: gastric emptying half time 
(GET½) when half the substrate has been metabolised, lag time (GETlag), the time of 
maximum gastric emptying speed, maximum gastric emptying time (GETmax), the peak of 
the percentage excretion curve and a gastric emptying coefficient (GEC) which describes 




Figure 1.4: Curve describing the cumulative excretion of C13 dose over time 
 
 
Figure 1.5: Curve describing the percentage of total C13 dose excretion over time 
The breath test is based on the fact that medium and short chain fatty acids are very 
quickly absorbed from the duodenum, transported to the liver for metabolism, 
converted to CO2 and then excreted in the breath (116).  Assuming that post absorptive 
processes are constant the rate-limiting step is gastric emptying (117, 118).  
In 1993 Ghoos (116) from the Leuven group in Belgium, published the first report 
comparing scintographically measured gastric emptying with C13 and the very similar 
C14 labelled sodium octanoate breath tests (OBT).  36 subjects were given a meal 
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labelled with both C14 and technetium.  GET½, GETlag and GEC were calculated using non-
linear regression. They found excellent correlation (r = -0.88 for GEC, 0.89 for GET½, and 
r = -0.92 for GETlag) between scintographic data and the oral  breath test (OBT).  In vitro 
studies were also performed to assess the label’s stability in the stomach. They found the 
label was stable and no statistically significant intra-individual or inter-individual 
variation. 
The Mayo group also validated C13 breath testing against scintography (119-122). They 
developed various models using generalised regression, which calculated the breath test 
emptying parameters using differently weighed 13-CO2 concentrations from various 
time points.  The hypothesis was that the post absorption metabolism was too different 
between individuals to apply the same correction for all subjects. If they applied the 
original non-linear regression model to their data, estimated steady state 13-CO2 
excretion (M) was often not steady even when all of the food had been shown to leave 
the stomach with technetium scanning (121, 122).  They found M was sometimes 
overestimated which would therefore lead to inaccuracies in the calculated gastric 
emptying time. Even extending the time collection period did not truly correct for this 
(119, 120). They proposed a generalised regression model that didn’t rely on M, using 
only three time points. In a comparison study of Ghoos’s method, scintography and their 
new model they found good agreement with scintography using the more simple 
approach (121). 
Since that time other generalised regression models have been devised using many 
different time points, mostly collecting data over 4 hours (121-124).  All have validity 
and good correlation for the meals that they have been tested against but applying the 
models to different meals without a validation process is unreliable (118). 
1.4.2 Application of the OBT test to children 
The OBT has since original inception been identified as a test desirable for use in 
children.  Studies have been done in both the liquid and solid phases to evaluate the 
reliability and suitability for children.  Most have followed the original paper by Ghoos 
and used nonlinear regression to calculate GET1/2, Tlag, Tmax and GEC (125-128). 
Not surprisingly there are limited studies that compare the OBT with “gold standard” 
scintography in children. In one of the only studies validating a solid sodium octanoate 
meal against technetium, 25 healthy children were given a meal containing both C13 and 
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technetium .  GET1/2, Tlag and GEC were measured, using Ghoo’s non-linear regression 
model.  Very good correlation was found for GET1/2 (r 0.92) and less strong but 
statistically significant correlation was found for Tlag.  
Hauser performed a recent study to first of all correlate scintography with a pancake 
OBT, then performed the OBT in 120 healthy children, to try and establish a normal 
range. They showed good correlation between the scintography and C13 test, (r 0.748), 
and also established a mean GET1/2 of 157.7 +/- 54 (71-415). They performed regression 
for gender, weight, height and body mass index (BMI), none of which affected gastric 
emptying, but with increasing age gastric emptying did increase (129). 
1.4.3 The OBT in T1DM 
Little has been published about children with diabetes using the OBT.  Some work has 
been done to investigate gastric emptying in adult diabetics using this method.  
An early study (130) evaluated the OBT in adults with both T1DM and T2DM.  The OBT 
and scintography were measured on two different days.  The OBT had as sensitivity of 
75% and specificity of 85% to detect delayed gastric emptying.  There was no 
statistically significant correlation between blood glucose levels, HbA1c or duration of 
diabetes. 
1.4.4 Using the OBT 
The OBT has been repeatedly shown to be comparable to scintography.  It can detect 
changes in gastric emptying with sensitivities approaching 100% in some studies.  It can 
reliably be used in children and in T1DM.  Interpretation must be tempered against the 
known drawbacks, including a lack of standardisation, not just of the meal but the 
method for interpreting the values generated.  It does represent a safe, repeatable, 
acceptable measure of gastric emptying. 
1.5 Gastrointestinal symptoms 
1.5.1 Symptoms in Children with T1DM 
Given the increased prevalence of coeliac disease and the potential for altered gastric 
emptying, it seems likely children with T1DM would experience gastrointestinal 
symptoms. Anecdotally clinicians report increased complaints of GI symptoms in 
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children with T1DM. It was this clinical observation that partly prompted the thesis 
question, however robust research examining this hypothesis is not abundant. 
There have been two studies that looked at the prevalence of GI symptoms in children 
with T1DM. Both studies found similar rates of GI symptoms in children with T1DM and 
healthy controls. The prevalence rates varied between the two studies, one reported a 
rate of around 30% (131) in both cases and controls and the other a rate around 70% 
(132). Methodology and control groups differed between the two studies.  
1.5.2 Prevalence of symptoms in healthy children 
Overall, gastrointestinal symptoms in children are common (133-135). A community 
based study, using a similar questionnaire to that used in this study, found weekly 
prevalence rates of 45% of any GI symptom and found that during the study period 90% 
of school aged children complained at some time of any GI complaint (133). 
Much of the work looking for symptoms has focused on finding the prevalence of 
Functional Gastrointestinal Disorders (FGID): GI symptom complexes that cause 
significant functional impairment (136). As with symptom complaints, FGID are also 
common in children. An excellent recent meta-analysis tried to pool data from around 
20,000 patients in regards to abdominal pain FGID (137). They demonstrated a 
prevalence of 13.5% (95% CI 11.8-15.3), although prevalence did vary greatly, from 
1.6% - 41.2% (137). 
As well as examining prevalence, the meta-analysis looked at factors associated with 
higher rates of pain. Girls had higher rates than boys, pooled OR 1.5 (95% CI 1.3-1.7, p 
0.01). Anxiety and depression were more frequent. Depression predicted a higher 
likelihood of a pain FGID, and a FGID predicted higher rates of depression. Pain 
disorders were also more likely in those who had experienced adverse life events (137).  
1.5.3 Measuring symptoms 
To assess GI symptoms in children most research has used questionnaire-based 
assessments. The two studies done in children with T1DM used different methods. 
Vazeou et al. (131) used an unidentified standardised questionnaire, administered by a 
single researcher. Lodefalk et al. (132) used postal questionnaires designed for use in 
adults, with 87 questions, some of which related to GI symptoms. 
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A large body of work has gone into developing questionnaires that are based on the 
Rome criteria for diagnosis of FGID (138). These are very long detailed questionnaires 
designed to make a diagnosis of functional gastrointestinal syndromes such as 
abdominal migraine, functional constipation or functional dyspepsia. 
None of these tools suited the population or aim of the current research. The tool that 
best matched was that used by Saps et al. (139). It was a simple questionnaire designed 
to establish the prevalence of GI symptoms in the previous week. It was designed to be 
filled in by school students each week, with an overall aim of determining intensity of 
symptoms. The questions from this questionnaire were in turn based on the Child 
Somatisation Inventory, a well-validated tool for identifying somatic conditions in 
children (140). 
1.5.4 Pathophysiology of GI symptoms in Children 
As described in the preceding sections, children with T1DM have higher rates of GI 
pathology that potentially could cause an increase in associated symptoms. However as 
demonstrated by the prevalence of symptoms in controls and community “well child” 
studies (133-135), in the majority of cases, children with gastrointestinal symptoms, 
particularly pain symptoms, do not have serious underlying pathology. In the absence of 
concerning signs (such as weight loss, bloody stool, physical findings) most abdominal 
pain in children does not have a serious cause (136). A cost analysis study of the 
investigations used for FGID showed that for $6000 of blood tests, radiology and 
endoscopy, almost no serious pathology was discovered (141). 
Children all over the world describe recurrent GI symptoms (135). The underlying 
reasons for the high prevalence of complains but lack of underlying pathology is 
multifactorial. Children have a limited vocabulary and ways to describe what they feel. 
Some may interpret feelings in their abdomen as pain where as others may use different 
words to describe the sensation (142). Parents interpret and react to complaints of pain 
in different ways (143). 
The pathogenesis of functional pain disorders is thought to be associated with altered 
gut motility, visceral hypersensitivity, abnormal brain/gut interaction, psychosocial 
disturbance and immune activation. The above factors are thought to work in conjuction 
to influence how the body feels pain, interprets and reacts to it (142). Notably early life 
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experiences and life stressors are a major influencing factor on the development of FGID 
(144). 
The gut is a complex organ system. It has important barrier and immune functions, 
which need to balance with its vital role in the digestion and absorption of nutrients 
(145). A network of reflex circuits and afferent pathways to the central nervous system 
interact to control these various functions. The pathways have receptors throughout the 
enteric system that respond to physical and chemical stimuli – such as distension and 
absorbed nutrients (146, 147). The receptors are modulated by many factors – they can 
be upregulated by inflammation and injury to become more sensitive, so that stimuli 
that may not cause a sensation of pain in one individual is interpreted as a negative 
sensation in another (146). One of the mediators of this upregulation is hypothesised to 
be the hypothalamic- pituitary - adrenal axis, which helps explain the consistent link 
between psychosocial stress and increased complaints of gastrointestinal symptoms, as 
this axis is switched on during times of stress (142, 145). 
Abnormal motility is involved in gastrointestinal symptoms. Psychosocial stress is a 
factor as emotional disturbance has been demonstrated to cause slowed gastric 
emptying but also stimulate colonic motor function (142). These symptoms include 
nausea and vomiting, abdominal pain and diarrhoea/constipation (146). In one study of 
children with functional dyspepsia, around 60% of the children had slower gastric 
emptying and/ or abnormal gastrography, suggesting altered gastric emptying  was a 
mechanism in the pathophysiology of this group of disorders (148). 
1.5.5 Relevance of GI symptoms to clinical practise 
The research undertaken in children with T1DM has not demonstrated any difference in 
prevalence of gastrointestinal symptoms, but the studies have been small and there are 
methodological difficulties particularly in terms of the control group and the selection of 
subjects – neither is truly representative of the general population of children with 
T1DM (131, 132). There are plausible mechanisms to explain the anecdotal findings of 
clinicians that children with T1DM suffer more GI symptoms, for instance increased 
psychological stress and altered gastric emptying, but evidence is preferable to 
anecdote. Knowledge of the rate and intensity of symptoms is important if clinicians are 
to adequately and competently address these complaints, both to identify pathology as 
well avoid unnecessary investigation. 
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1.6 Hypothesis/research questions: 
This thesis aims to explore the gastrointestinal manifestations of T1DM. Three areas 
were chosen for particular study: CD, GI symptom complaints and gastric emptying 
rates. 
1.6.1 Coeliac Disease Screening Benchmark 
CD and T1DM are common co-diagnoses and probably have common causal 
mechanisms. Screening for CD in T1DM has been mooted as worthwhile by many 
international bodies (50, 149). However, clinical experience suggested that clear 
guidance was not easily accessible, and different clinicians had different practise.  To 
help clarify a standard approach, this thesis aimed to create an accurate picture of 
current practice for screening and management of CD amongst clinicians caring for 
children with T1DM in New Zealand (NZ).  
1.6.2 Gastric Emptying Rates in children with T1DM 
Gastric emptying impacts on blood glucose control and blood glucose levels influence 
gastric emptying. To understand this relationship, a good knowledge of gastric emptying 
is required. Adults have high rates of gastroparesis but rates of gastric emptying have 
not clearly been demonstrated to be either rapid or delayed. This thesis hypothesised 
that gastric emptying will be delayed in children with T1DM 
We aimed to compare gastric emptying in children with T1DM to that in healthy 
controls. Secondary objectives are to determine the impact of Body Mass Index (BMI), 
glucose control, age, gender and duration of disease upon emptying in children with 
T1DM. 
1.6.3 GI symptoms in children with T1DM 
There are plausible reasons that children with T1DM should have high rates of GI 
symptoms, both due to increased rates of CD, potentially altered gastric emptying as 
well as possible psychological differences. Evidence demonstrating a difference in 
symptoms is minimal. 




We aimed to prospectively establish the rate and intensity of GI symptoms in a clinic 





 Chapter Two: Screening for Coeliac Disease in Type One Diabetes 
2.1 Introduction 
In New Zealand the incidence of T1DM has been observed to be 17.9/100000 (15), 
which is one of the highest rates in the world (18, 150). T1DM is strongly associated 
with certain HLA subtypes (31) although other genes as well as environmental factors 
have potential causal roles (10). T1DM is associated with increased risk of other 
autoimmune diseases, including coeliac disease (CD) (149). 
CD is also strongly associated with certain HLA subtypes and is caused by a complex 
interaction of genetic and environmental factors (50).  CD may present in several ways: 
the “classical” picture of malabsorption; the “non-classical” scenario, which may include 
various symptoms such as chronic abdominal pain, short stature or anaemia; and the 
increasingly recognised ‘subclinical” disease, which is asymptomatic on routine clinical 
assessment (51).  
Prevalence studies from around the world have established that CD is more frequent in 
T1DM (58, 151-155). Rates vary from 2.4% (58) to 16.4% (154). A meta-analysis 
including Australian children found a pooled prevalence rate of 5.1% (CI 3.1-7.4%) (9), 
illustrating a substantial increase from the 1% rate of CD in the general population (54).   
The two diseases share HLA subtypes.  CD is potentially involved in the aetiology of 
T1DM, it has been postulated that increased intestinal permeability seen in CD could 
allow environmental antigens access to spark the immune processes leading to T1DM 
(10, 31). 
In the last decade the presentation patterns of CD have changed greatly, with more non-
classical or subclinical cases diagnosed and fewer classical presentations (156, 157). 
This is especially true in children with T1DM where up to 71% are reported to be 
asymptomatic at presentation (157). This pattern of CD in T1DM reflects in part the 
introduction of active screening programmes in some diabetes clinics. However the role 
of screening and the optimal screening system remain controversial (50, 149, 158).  
Most international bodies recommend screening, but how and how often is not clear, as 
summarised in Table 2.1.  The 2011 Australian Paediatric Endocrine Group diabetes 
management guideline suggests screening at diagnosis and once in the next 5 years but 
offer no suggestion as to which antibodies to use (149), whereas the 2012 European 
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Society for Paediatric Gastroenterology, Hepatology and Nutrition Celiac Disease 
management guidelines suggest establishing the HLA subtype at diagnosis and 
proceeding to screen at diagnosis and every 2 – 3 years subsequently only if at risk (50). 
Due to the conflicting nature of this advice it is unclear how clinicians actually approach 
the issue. A recent North American postal survey of health professionals looking after 
adults found very varied screening practices (159). We aimed to create an accurate 
picture of current practice for screening and management of CD amongst clinicians 












Frequency of screening 
International Society for Paediatric 
and Adolescent Diabetes (160) 
2014 At diagnosis TTG and/or EMA, IgA Annually for first 5 years, then every second 
year. More frequently if first degree relative 
with CD or suggestive symptoms 
Australian Paediatric Endocrine 
Group (149) 
2011 Screen at diagnosis in 
children and 
adolescents 
Not specified If negative, should be rescreened, at least once 
in the first 5 years after diagnosis 
European Society for Paediatric 
Gastroenterology, Hepatology and 
Nutrition (50) 
2012 Not specified Start with HLA type, if 
positive then TTG and 
IgA, EMA if weak 
positive 
Retest at intervals, no firm evidence but 
opinion is every 2 to 3 years 
National Institute for Health and 
Clinical Excellence (158) 
2009 Not specified  TTG initially, check 
IgA if serology 
negative 
Insufficient evidence to make a 
recommendation 




2.2 Materials and Methods 
2.2.1 Participants and inclusion criteria 
Consultant paediatricians and adult physicians who cared for children under 15 years 
with T1DM in secondary or tertiary hospital clinics around NZ were invited to complete 
a questionnaire. A comprehensive list of consultants caring for children with T1DM was 
compiled. The list was created from the Novonordisk Endocrine Workshop 2010 
invitees list.  Every District Health Board’s Paediatric Outpatient Department was 
contacted to enquire who ran diabetes clinics.  Invitees were also asked to recommend 
other consultants who should be on the list.  The list was also discussed with a 
paediatric endocrinologist to ensure there were no omissions. 
Each consultant was sent an email inviting participation in the study. Non-responding 
consultants were sent a further email reminding them of their invitation. Subsequently, 
the respondents who still had not responded were sent a paper copy of the 
questionnaire and asked to return it by mail or hand.   
2.2.2 Survey Design 
An online questionnaire was designed by the investigator using Surveygizmo 
(www.surveygizmo.com). The questions were written to discover the participants’ 
current practise regarding screening and management of CD in NZ children with T1DM.  
Areas covered were departmental screening procedures, the individual’s own screening 
practices and the management of CD after diagnosis. The questionnaire was a mixture of 
multiple choice and open-ended questions. Answers to open ended questions were 
grouped for interpretation. (Appendix A).  The survey was reviewed by supervisors and 
an impartial clinician and feedback was incorporated. The survey was open from 
October 2010 until January 2011. 
2.2.3 Ethical Approval 
Ethical approval was not sought as this was a benchmarking exercise. Similarly consent 
was implied by participation in the survey. 
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2.3 Results  
2.3.1 Respondents  
Of the 37 consultants invited, 34 responded (Table 2.2).  
Table 2.2: Clinical role of respondents to questionnaire 
Clinical role Number of respondents 
(n=34) 





General paediatrician 26 28 
Adult physician 1 1 
Neonatologist 1 1 
 
2.3.2 Demographics 
The reported number of children with T1DM cared for by individual participants ranged 
from 6 to 400.  The respondents estimated that between 0 and 30% of children in their 
T1DM clinic had been diagnosed with CD.  
2.3.3 Screening protocols 
Twenty-one of the respondents have a formal departmental protocol for screening for 
CD in their population of children with T1DM. Regardless of departmental protocol the 
respondents were asked about their individual practice. Twenty-five of the consultants 
screen for CD at diagnosis of T1DM. Of those who do screen, all use anti-tissue 
transglutaminase antibodies (TTG), some also use anti-endomysial antibodies (EMA) 
and a few use other antibodies.  
Twenty-one of the respondents who screen at diagnosis subsequently screen for CD 
every 1-2 years. The other four use symptoms and/or the patient’s age as a trigger to 
rescreen. 
The nine consultants who don’t regularly screen at diagnosis were asked what if 
anything did trigger them to screen (Table 2.3). All use tTG to test for CD when they do 
screen, with most also using EMA, one adding antigliadin antibodies and one clinician 




 Table 2.3: Clinical indication to test for coeliac disease in a patient with type one diabetes 
mellitus 
Indication  (More than one  response was allowed) No of respondents (n=9) 
Poor growth 8 
Gastrointestinal symptoms 7 
Erratic blood sugar control 6 
Diarrhoea 6 
Anaemia 6 
Family history 5 
Recurrent hypoglycaemia 5 
No response 1 
(Respondents who don’t screen at diagnosis were asked what features of a case would prompt them to 
test for CD) 
 
2.3.4 Management after screening positive 
After a child was found to have abnormal screening tests, 29/34 participants would 
refer for a small bowel biopsy. Some qualified the decision to proceed to biopsy with the 
strength of the positive test, the child’s symptoms, HLA status and discussion with the 
family.  Nine would repeat bloods at the same time as referring for biopsy. Two typically 
commenced a gluten free diet (GFD) prior to or while awaiting biopsy. 
2.3.5 Gluten Free Diet 
Thirty-two of the consultants responded that biopsy proven CD was their criteria for 
commencing a GFD.   
2.3.6 Management of symptom free CD 
When asked in an open-ended question how they approach subclinical CD, 30/34 
consultants said they advise a GFD. Three qualified this further by mentioning that 
“symptom free” patients often feel better when on a GFD.  Seven said they discuss “the 
pros and cons” with parents and patient to allow them to evaluate the decision to 
commence a GFD.  One practitioner reported that they only test symptomatic cases so 
has no “routine” practice with asymptomatic children. 
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2.3.7 Management if Gluten Free Diet is declined 
In an open-ended question, clinicians were asked what their approach was when a 
diagnosis of CD had been made but the patient declined starting a GFD. Thirty-two 
consultants responded. The responses were very varied but were grouped for analysis.  
Some responses were placed into more than one category. Fourteen will try to educate 
the family, 7 will accept their patients’ decision, 14 will provide on-going monitoring and 
4 had not encountered the situation. Most clinicians will try and provide the family with 
adequate information to make a choice, but will not force the issue. If a GFD diet is 
declined they will continue to monitor the situation, allowing room for on-going 
education and the ability to re-approach the decision when appropriate.  Several 
comment on the lack of certainty as to the benefits of a GFD especially in asymptomatic 
disease. 
2.4 Discussion 
Whilst there are common trends, the responses to this survey demonstrate the varied 
approaches taken when dealing with CD in children with T1DM in NZ. Over half the 
clinicians surveyed formally screen for CD, but nearly one third do not. This survey 
represents the majority of clinicians looking after children with T1DM in NZ with a 92% 
return rate and as such is a good representation of the current approach to CD in the 
setting of T1DM in the NZ setting. 
The complications of untreated symptomatic CD are well documented and include 
growth failure, increased fracture risk, and gastrointestinal malignancy (158). Children 
with T1DM have further potential complications such as impaired growth, 
hypoglycaemia and osteopenia as well as renal, cardiovascular and eye problems (149). 
How these complications manifest when CD and T1DM coexist has not been well 
established. One study looking at cohorts of children with CD and CD &T1DM has 
suggested that the clinical picture in dual diagnosis is in fact milder than in children with 
CD alone (161), although this has not been repeated (162). 
Many of the clinicians in the current study who don’t have a regular screening 
programme use poor growth or poor diabetic control as indicators to commence 
screening for CD. The available evidence, however, is not conclusive as to the impact of 
CD upon growth or glycaemic control. It is even less conclusive as to how starting a GFD 
will improve these clinical markers. Many studies are limited by small numbers, unclear 
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definition of symptomatic versus screening detected CD and a lack of adequate 
consideration of bias from variables such as compliance and pubertal status. 
Gluten free food is often less palatable than gluten containing food and often contains 
less complex carbohydrates, which can lead to rapid peaks and troughs in blood glucose 
control. This could mean that blood glucose control is more challenging for families, 
although evidence is limited that demonstrates that this translates into poor control, as 
measured by HbA1c (163-169). 
Two small studies found statistically significant differences in the rate of hypoglycaemia 
in screening detected children prior to discovery of CD that resolved after diagnosis 
(165, 166). However, several other studies including a large observational study (411 
T1DM with biopsy-proven CD) found no difference in reported severe hypoglycaemia at 
diagnosis (163, 167, 168).  A population-based study in Sweden examined the hospital 
records of all children diagnosed with CD&T1DM, and found no difference in the rate of 
hypoglycaemia admissions, diabetic ketoacidosis or death (170). Untreated CD may 
increase the risk of potentially serious hypoglycaemia and the response to foods aimed 
to correct it but this has not been well studied. 
HbA1c is often used as a measure of overall control in T1DM.  Many studies have tried in 
various ways to elucidate the impact of CD upon HbA1c in T1DM, both prior to diagnosis 
and after initiation of a GFD.  The majority of reports have found no difference in HbA1c 
either at diagnosis between cases and controls or after starting a GFD (Table 2.4).  Two 
studies found lower HbA1c in cases than controls, which increased to that of controls 
after GFD was commenced (164, 169).  However, when one of the groups repeated the 
study some years later, this difference was no longer evident (163).  The inclusion and 





Table 2.4: Summary of glycosylated haemoglobin (HbA1c) results in recent papers evaluating glycaemic control in children with coeliac disease (CD) and type 
one diabetes mellitus (T1DM) 
Author (year) N=cases N=controls 





HBA1c cases on GFD 
(yrs of follow up) 
p 
Artz (171)(2008) 30  † 34 8.04 ± 0.2 8.05±0.1 0.89 - - 




Kaspers (164) (2004) 127 ‡ 18470 8.1±1.8 8.8 ±2.4 <0.05 ¶  
Rami (168) (2005) 98 ‡ 195 8.8 ± 2.2 9.3 ±2.5 0.35   
Saadah (172) (2004) 21 ‡ 42 8.03 ± 0.9 8.21 ±1.2 ns 8.04 ±0.98 (1yr) ns 
Simmons (167)(2011) 79 § 56 8.3 ±0.2 8.1 ± 0.1 0.29 8.1 ± 0.2 (2 yrs) 0.32 
Sun (169) (2009) 49 ‡ 49 8.4 ±1.3 8.7 ±0.9 <0.001 8.9 ± 1.5 v 8.8 ± 1.5 (cases 
v controls) (1yr) 
0.9 
Key: 
†  seropositive to either TTG or anti-endomysial antibodies 
‡   Biopsy proven coeliac disease 
§   anti-tissue transglutaminase positive (TTG) 





Poor growth has been identified by the respondents to this survey as a prompt to screen 
for CD. It is not clear if growth is commonly affected in subclinical CD or that starting a 
GFD improves growth parameters.  Three studies have shown impaired growth 
parameters in subclinical CD discovered in screening programmes. The largest study 
found lower height and weight scores in biopsy proven CD, which was persistent despite 
commencing a GFD, although no attempt was made to identify if compliance altered the 
result (163).  One of the other studies found lower height and weight at diagnosis, of 
which weight improved but not height unless the children were younger than 14 years 
(165).  The third study found a reduced body mass index (BMI) at diagnosis, which if the 
children were compliant then increased to match controls after 2 years (167). Four 
other case control studies found no difference in growth parameters at diagnosis (162, 
168, 169, 173). This persisted in three of the studies (162, 169, 173) whilst the other 
found that after diagnosis weight gain was slightly poorer in those with CD (168). 
Reduced bone mineral density has been found in children with both T1DM (174) and CD 
(175) independently.  Studies have shown that children with T1DM and CD also have 
reduced bone mineral density (BMD) (176, 177). A cross sectional study of 122 children 
with T1DM and positive CD serology, matched with 129 children with only T1DM, 
showed that 12% of the children with positive serology had low BMD, compared to 3% 
without TTG antibodies (p0.0076) (178). GFD has been shown to be associated with 
better BMD in CD (177, 179, 180) and the dual diagnosis (171, 176).  Recognising CD 
early and establishing treatment to avoid future fractures could be a convincing 
argument for screening, but here also, evidence conflicts. One study using Swedish 
population data did not find an increased fracture risk in young people with dual 
diagnosis, but the follow up of a median of 13 years, does not seem long enough to be 
able to ascertain the impact of osteoporotic fractures and as a purely retrospective, 
observational study it cannot give information on how treating the disease with a GFD 
will impact on outcomes (181). 
Epidemiological studies have shown that there is increased risk of death in both CD and 
T1DM.  This is thought to relate to both cancer risk and increased atherosclerotic 
complications.  A large retrospective population based Swedish study found that 15 
years after CD diagnosis the adjusted hazard ratio for mortality in patients with T1DM 
was 2.8 (95% CI 1.28-6.12) (182). Both cancer risk and increased atherosclerotic 
complications have independently been found to be significant causes of death when 
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each illness is diagnosed alone (183, 184).  Observational studies regarding 
microvascular complications in large cohorts of young people with T1DM, also suggests 
that there is an increased risk of eye, renal and neurological complications in T1DM and 
CD(185-187) . Because such studies are necessarily retrospective and there are many 
confounding factors, it is difficult to make comment on how recognising and treating CD 
would change this risk.  
Several clinicians who do not screen for CD stated that they use symptoms to trigger 
testing. Some studies in children with T1DM and CD have found a low rate of reported 
symptoms although some of these studies rely on retrospectively collected data or chart 
review (157, 167). Other studies demonstrate that by the time the CD diagnosis is made 
the majority of patients will report symptoms prior to starting a GFD (165, 188). Some 
NZ clinicians note asymptomatic cases often report feeling better once a GFD has been 
started. This could be due to lack of direct questioning, patients simply putting up with 
vague symptoms that they only recognise once resolved or that there is a certain 
placebo effect of being on a GFD.  A recent report from the TEDDY birth cohort study 
group showed that symptoms of abdominal discomfort and GI upset were more 
commonly reported when caregivers were aware of CD immunity than before they were 
aware (189). 
Given the difficulty of identifying CD in a clinical setting, the high incidence and the 
evidence pointing towards negative consequences of untreated CD, the weight of expert 
opinion suggests that screening is prudent. Most NZ clinicians do screen for CD in their 
T1DM populations. The most commonly used tests are TTG and EMA. TTG is a more 
objective assay than EMA but has more false positives as it can be raised in other clinical 
situations, including at diagnosis of T1DM, after which it has been demonstrated to 
normalise(151, 190, 191). Antigliadin antibodies (AGA) are limited in their sensitivity 
and specificity and are not now recommended for screening (158). The most recent 
European guidelines suggest that HLA subtyping be done in at risk groups and if 
negative for DQ2/DQ8 then no further testing be done (50, 158). Work in clinical 
populations has suggested however this strategy may not be as useful in children with 
T1DM as there is a high rate of the HLA subtype DQ2/DQ8 – 95% in one Scottish group 
(192), and 86% in a Dutch group (193). Very few NZ clinicians test for HLA, perhaps 
reflecting difficulty and expense of accessing the test as well as its limited usefulness for 
discriminating children at risk. 
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NZ clinicians screen yearly or biannually with some modifying this with age or years 
since T1DM diagnosis.  Most children are diagnosed with CD within 2 years of diabetes 
diagnosis but cases continue to be identified over at least the next 10 years (9, 155, 194). 
International recommendations vary from yearly screening to once initially at diagnosis 
and then once in the next 5 years (50, 149, 195). It has been shown that there is a higher 
prevalence of CD in children with a younger age at T1DM diagnosis (163, 191, 194, 196), 
suggesting that screening should be extended in children younger than 5 years at the 
onset of diabetes. 
The only current treatment for CD once discovered is a life-long GFD.  This can be a 
burdensome and expensive cure. Some studies report compliance rates as low as 25% in 
patients with both CD and T1DM (172).  A major concern for clinicians and patients is 
the effect of GFD on quality of life (QOL).  
In symptomatic CD, QOL and perceived wellness generally improves after 
commencement of a GFD (197). When subclinical cases of CD are evaluated there seems 
to be very little change in QOL with GFD (198). Two questionnaire studies in T1DM 
children found no difference in QOL score in children with or without CD (199, 200).  
This work suggests that the impact of a CD diagnosis may not be as significant as feared. 
A repeated observation when trying to determine if screening is worthwhile in 
populations with CD and T1DM is the benefit of treating with a GFD. Any work that has 
tried to look at the impact of the dual diagnosis can only really comment on the 
parameters at diagnosis, and the benefit of GFD is muddied by questions over 
compliance with a GFD. A study is currently under way that will help determine if 
making the diagnosis when a child is asymptomatic is important as it aims to evaluate 
the benefits of GFD in asymptomatic CD in T1DM by randomising participants to GFD or 
usual diet (201). 
2.5 Conclusion 
In conclusion, this work demonstrates that screening for CD is undertaken by nearly all 
clinicians but that there are in variations in practise.  Clinicians caring for patients are 
sensitive to the burden of T1DM and the extra burden another diagnosis may place upon 
the family.  If there is symptomatic CD the path is clear, and a GFD will help alleviate 
symptoms and avoid malabsorption.  In subclinical disease the case is less clear, but 
there are possibly benefits to bone, growth and diabetic control with minimal impact on 
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quality of life. A nationwide consensus on screening, would help avoid confusion, 
particularly when patients move from one clinic to another.  Further research with large 
multicentre prospective cohorts of children with agreed definitions of CD, GFD and 
growth parameters will help provide definitive answers as to the benefit to be derived 





 Chapter Three: Gastric Emptying in Children with T1DM and healthy 
controls 
3.1 Introduction 
T1DM is a multisystem disease of glucose homeostasis (202). Good blood glucose 
control has been shown to improve long-term outcomes (78). Gastric emptying has an 
impact on post-prandial glycaemia. Rapid gastric emptying may be responsible for 
elevated postprandial blood glucose, therefore impacting on overall glycamia (93, 103, 
106). Synthetic agents such as pramilinitide are available which alter gastric emptying 
and by inference regulate postprandial hyperglycaemia, an important determinant of 
overall control (110, 203). Without knowledge of the physiology of gastric emptying in 
T1DM children the utility of these adjuncts is limited (204, 205). 
Several studies using varied methodologies have examined gastric emptying in children 
and adolescents with T1DM. Although most studies demonstrated altered emptying, two 
with the most robust methodologies did not show any change (88, 90-94, 206). 
With the underlying hypothesis that children with T1DM would have delayed gastric 
emptying compared to healthy controls, the current study evaluated gastric emptying 
using a safe non-invasive method. The primary objective of this prospective pilot study 
was to compare emptying in children with T1DM with that in healthy controls. Further 
objectives were to elucidate the impact of Body Mass Index (BMI), glucose control, age, 
gender and duration of disease upon emptying in children with T1DM. 
3.2 Subjects and Methods 
3.2.1 Cases and Controls 
Children with T1DM (defined by standard clinical criteria) (202) were recruited from 
the paediatric diabetes clinic at Christchurch Hospital, Christchurch, NZ.  Inclusion 
criteria was broad to encourage recruitment. All children aged between 7 and 15 years 
old with diagnosis of T1DM for longer than six months were approached by a single 
researcher. Cases were excluded if they had known underlying GI or other medical 
illness (other than T1DM), or poor diabetic control as defined by recurrent severe 
hypoglycaemia, recent diabetic ketoacidosis, or HbaA1c >14% (130mmol/mol).  Cases 
 
 42 
were asked to recruit a control, either a peer or siblings of the case without T1DM or any 
known underlying GI or serious medical illness.  
Demographic data was collected on participants. All caregivers filled in a questionnaire 
regarding GI symptoms in the children (see Chapter 4 for description of questionnaire). 
Responses were marked on a 5-point likert scale. The response to each question was 
added together to give an overall symptom score.  
3.2.2 Breath Testing Protocol 
The Carbon 13 (C13) oral breath test methodology as developed by collaborators in 
Adelaide was followed (Zacharias & Butler, University of Adelaide personal 
communication). This method is a safe, easily reproducible measure of gastric emptying 
that compares favourably to the gold standard scintography for measuring gastric 
emptying in children(128). The method follows that developed and validated by Ghoos 
where samples of exhaled carbon dioxide is collected at various time points, then 
analysed to give measures of the rate of gastric emptying. (116). Each subject’s Gastric 
Emptying Coefficient (GEC), gastric half emptying time (GET½) and maximum gastric 
emptying time (GETmax) were calculated using linear regression, in a method developed 
by Ghoos (116).  
Subjects fasted overnight and then consumed a standardised pancake meal for 
breakfast.  The meal consisted of 70g of pancake mix (Edmonds, Auckland, New 
Zealand) mixed with 100ml of filtered water and 100mcg of sodium octanoate enriched 
with Carbon 13 (C13) (Cambridge Isotope Laboratories, Andover, Mass, USA). The 
pancake was cooked in 5g of butter, and served with the option of 5g of glucose free jam.  
The meal was eaten within 10 minutes. No other food was consumed for the duration of 
the test but subjects were allowed to sip small amounts of water. 
Cases administered their usual insulin regime, with an adjustment in the dose if 
necessary to allow for a smaller carbohydrate meal than their usual breakfast after 
measuring a baseline blood glucose and in consultation with their caregiver. 
Breath samples were collected into a test tube via a drinking straw at baseline, then 
every 15 minutes from the start of the meal until 120 minutes, then every 30 minutes 
until 240 minutes.  Cases measured their capillary blood glucose (BSL) on their own 
glucometer at baseline and then every hour or if symptomatic.  Low BSL (<3.5 mmol/L) 
were corrected with 10g of dextrose and a small mixed meal. High BSL (>20 mmol/L) 
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were corrected with rapid acting insulin. Cases developing hypoglycaemia were 
excluded from final analysis. 
3.2.3 Statistical Analysis 
This study was intended as a pilot study. The number of children recruited was a 
convenience sample.   
Samples were analysed on an (Sercon) ABCA isotope ratio mass spectrometer (Crewe, 
UK), at the University of South Australia.  
Results were analysed using Stata/IC 12.1 for Windows. Data are presented as mean and 
95% confidence intervals as appropriate. Mean values were compared using two sample 
t-tests. P<0.05 was considered statistically significant. Correlation was examined using 
Pearson correlation. Ethical approval was granted to the study by the Upper South A 
Regional Ethics Committee, Christchurch New Zealand (Appendix B). Informed consent 
was attained from the guardian and children prior to entry into the study. 
3.3 Results 
3.3.1  Demographics 
Breath testing was performed on 20 cases and 15 controls. Six cases were excluded from 
primary analysis as they had hypoglycaemia requiring treatment during their study, 
leaving a final group of 14 children with T1DM. In post-hoc analysis, the children were 
divided into two groups that reflected the duration of T1DM: eight of the children had 
longstanding (defined as greater than 5 years since diagnosis) T1DM (mean 8 years, 
range 6 – 10 years) and 6 children had early T1DM (defined as less than 5 years since 
diagnosis) (mean 2 years, range 0 – 4 years). Demographic data comparing the children 
are presented in Table 3.1. All but one of the cases was on multiple daily dose regime of 
insulin, with a mixture of long, intermediate and short acting insulin. The remaining 





Table 3.1: Demographic data of participants 
 (n) Age in 
years 





BMI Z score 
Control 15 11.2 (2.6) 9   0.37 (0.10) 
Cases 14 11.3 (1.7) 8 5.4 (3.4) 9.2/77 
(1.1/12.5) 
0.56 (0.62) 
Early T1DM 6 11.6 (2.1) 5 2 (1.4) 9.6/81 
(0.5/5.2) 
0.44 (0.46) 
Longstanding T1DM 8 11.1 (1.3) 3 8 (1.5) 8.9/74 
(0.4/4.3) 
0.65 (0.73) 
Hypoglycaemic Cases* 6 11.4 (2.5) 4 4 (3.1) 8.4/68 
(0.6/6.6) 
0.13 (0.69) 
Data reported as median values (Standard Deviation). P > 0.05 in all comparisons. 
*Cases who developed hypoglycaemia during test and who were excluded from primary analysis. 
 
3.3.2 Gastric emptying rates 
The mean GEC in cases was higher than in controls, indicating a shorter gastric emptying 
time (3.19 (2.97 – 3.41) vs 2.90 (2.74 - 3.10), p = 0.03) (Figure 3.1). 
Mean GET½ was not statistically different between the two groups (cases 99 (68 - 128) 
mins vs 103 (88-118) mins, p = 0.8), but did tend to a shorter half time in cases (Figure 
3.2). GETmax values were similar in the two groups (cases 106 (88-128) mins vs 105 (94 




Figure 3.1: Gastric emptying coefficient (GEC) in cases and controls 
 
 





Figure 3.3: Gastric emptying Tmax in cases and controls 
 
3.3.3 Gastric emptying in longstanding compared to recently diagnosed T1DM 
None of the gastric emptying parameters were different between those with early and 
longstanding diabetes, although the children with a longstanding diagnosis tended to a 
shorter GET½ and higher GEC (Table 3.2 and Figure 3.4 – 3.6). When the outlier with an 
extremely long emptying time was removed, the GET½ approached statistical 
significance. There was a weak positive correlation between duration of T1DM and GEC, 
r = 0.4 (Figure 3.7). There was no relationship between duration and other parameters 
(Figures 3.8 and 3.9) 
Table 3.2: Comparison of gastric emptying parameters in children with Longstanding compared to 
Early T1DM 
 Early T1DM Longstanding T1DM p 
GEC 3.32 (2.83-3.19) 3.01 (2.94-3.67) 0.13 
GETmax (Mins) 101 (81-120) 110 (71-150) 0.66 
GET½(Mins) 104 (68-139) 95 (41-149) 0.77 














Figure 3.6: Gastric emptying Tmax in cases with longstanding or early T1DM compared to controls 
 
 





Figure 3.8: Gastric emptying T½ correlated with duration of T1DM, r =0 
 
 




3.3.4 The impact of other factors upon gastric emptying  
Amongst children with TIDM there was no correlation with any of the measured gastric 
emptying parameters and Glycosylated haemoglobin (HbA1c) (Table 3.3). 




GETmax (Mins) 0.4 
GET½(Mins) 0.2 
 
GEC, GETmax and GET½ did not correlate with BMI z-score, symptom score or age (Table 
3.4). 
Table 3.4: Gastric emptying parameters correlated with hypothesised modifiers of gastric 
emptying, r values 
 Symptom score BMI Z-score Age 
GEC 0.2 0.2 0.1 
GETmax (Mins) 0.0 0.0 0.0 
GET½(Mins) -0.1 -0.1 -0.1 
 
There was no difference in the mean emptying parameters between genders (Table 3.5). 
Table 3.5: Comparison of gastric emptying parameters by gender, mean value (95% confidence 
interval) 
 Male Female p 
GEC 3.12 (2.88-3.37) 3.04 (2.85 – 3.23) 0.6 
GETmax (Mins) 105 (94-115) 103 (88-118) 0.9 
GET½(Mins) 103 (74-133) 93 (79-107) 0.4 
 
3.3.5 Gastric emptying in cases initially excluded due to hypoglycaemia. 




Figure 3.10: Cases’ capillary blood glucose during breath testing study  
 
GEC, GET½ and GETmax were also calculated for the six cases who became hypoglycaemic, 
using the breath samples taken up until symptomatic hypoglycaemia. The addition of 
these values to the original data set did not alter the overall results: the GEC was still 
statistically significantly higher (p= 0.03) whilst the other parameters were not different 
(Tables 3.6 and 3.7). 
Table 3.6: Reanalysis of gastric emptying parameters including cases initially excluded due to 
hypoglycaemia. Mean value (95% confidence interval) 
 Cases including 
hypoglycaemia 
Controls p 
GEC 3.21(3.00 -3.42) 2.90 (2.74-3.06) 0.03 
GETmax (Mins) 103 (88-118) 105 (88-118) 0.9 





Table 3.7: Comparison of gastric emptying parameters between cases who became hypoglycaemic 
and those who did not, Mean value (95% confidence interval) 
 Cases as initially analysed Cases including 
hypoglycaemia 
GEC 3.19(2.97-3.41) 3.21(3.00 -3.42) 
GETmax (Mins) 106(88-128) 103 (88-118) 
GET½(Mins) 99 (88-128) 92 (70-115) 
 
3.4 Discussion 
The initial hypothesis of this work was that gastric emptying would be delayed in 
children with T1DM. The results arising however, demonstrated that gastric empting 
was faster in children with T1DM, when measured by the GEC. This finding was 
supported by a shorter GET½ in cases.  
The GEC is an index of gastric emptying: it describes the entire shape of the gastric 
emptying curve and is derived from measured CO2 excretion. The original paper that 
established the efficacy of C13 breath tests as a method for measuring gastric emptying 
found the GEC had the best correlation with scintigraphically derived gastric emptying 
curves (correlation coefficient: 0.94) and was sensitive and specific when looking for 
delayed gastric emptying (116). GEC could be thought of as a more precise measure than 
GET½, which had a correlation with scintigraphy of 0.79 (116).  
A limited number of studies have investigated gastric emptying in children with T1DM. 
Although methodological differences make direct comparison difficult, the reported 
studies show conflicting results.  Two studies (88, 206) used electrogastrography (EGG), 
a proxy measure of gastric emptying with limited clinical usefulness (207). Another 
study combined EGG with ultrasound to ascertain delay in emptying (90). All the EGG 
studies reported differences in gastric activity between children with T1DM and healthy 
controls. Four other studies used more direct measures of gastric emptying: 
scintography and C13 breath testing. Two scintography studies found no difference in 
gastric emptying (91, 92), whilst one study using C13 breath testing demonstrated 
significantly delayed gastric emptying (93), the other significantly faster gastric 
emptying in the adolescents they evaluated (95). Another study that included 
adolescents and young adults used a further technique, electrical impedence 
tomography, to measure gastric emptying and found a longer GET½ in cases (94).   
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Only one of the published paediatric studies demonstrated gastric emptying to be 
accelerated in children with T1DM. Acceleration of emptying has also been shown in 
studies of adult patients with both T1DM and T2DM (85, 86).  
Gastric emptying is a complex process controlled by hormonal and neurological 
mechanisms, which interact to produce a smooth supply of substrate to the rest of the 
digestive system (8).  Glycaemic, neuronal and hormonal pathophysiology can be 
examined to find hypotheses to explain the current results. 
It has been established that gastric emptying is accelerated when blood glucose is low 
(208) and decelerates when it is high (102). The children in this study were not on an 
insulin clamp. The blood glucose of the cases did not remain in the physiological range 
as demonstrated by the children who became hypoglycaemic or had initial 
hyperglycaemia (Figure 3.6). However the expected effects of these blood glucose 
changes were not seen. Gastric emptying was still faster when children with 
hypoglycaemia were initially excluded. As a number of children were hyperglycaemic it 
could have been expected that this would result in overall slower gastric emptying in 
cases, which was not seen.  The C13 breath testing study that demonstrated faster gastric 
emptying in adolescents noted that faster gastric emptying correlated with a bigger post 
prandial rise in blood glucose (95). These findings and those of the current study 
suggest that other mechanisms than direct glycaemic changes are implicated. 
The autonomic and enteric nervous systems are both involved in gastric emptying (8) 
and changes secondary to T1DM could have a bearing on the results seen. Autonomic 
neuropathy (AN) is believed to be very important in the pathophysiology of 
gastroparesis in adults (8). However the role AN plays in altered gastric emptying in 
children with T1DM is less well studied. AN is rare at the onset of diabetes, rising to 
about 12.2% after the diagnosis of T1DM has been established for more than 9 years 
(113). AN was an exclusion criteria in most of the studies that examined gastric 
emptying in children but few children met the criteria to be excluded. Three studies 
tried to look for a relationship between AN and gastric emptying, however no 
relationship was found (92, 94, 95).  The current study did not look specifically at 
measures of autonomic dysfunction, as it was assumed these would be subtle and not 
manifest in this population group, therefore no comment can be made about the impact 
it has made on the current results.   
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An interesting theory to explain the observed acceleration in gastric emptying is that 
rather than there being a mechanism causing accelerated gastric emptying, the cases in 
fact lacked a mechanism to slow their gastric emptying in response to the 
hyperglycaemia (209). Amylin (Islet amyloid polypeptide) is co-secreted from 
pancreatic beta cells with insulin and children with T1DM have reduced levels of this 
hormone (104). Amylin has been shown to inhibit gastric emptying in healthy controls 
in response to hyperglycaemia (85, 102). Administering synthetic pramlintide, an 
amylin analogue, to adults with T1DM resulted in gastric emptying rates slowing to 
equal to those of controls (85). It may be that the faster GEC observed in the cases in the 
current study was due to an inability to slow gastric emptying in response to the meal.  
Grhelin, another gut hormone, has been shown to accelerate gastric emptying (107) and 
is elevated in children with early T1DM (104, 108). In an animal study, antagonising 
grehlin resulted in gastric emptying rates slowing to that of controls (210).  
The limited size of the study means that it is inadequately powered to be confident the 
result is not due to type two error. As it was a pilot study, power calculations were not 
initially performed, but subsequent analysis suggest that a group of 21 in each group 
would be powered to 80%. Children with very poor control were excluded from the 
study for practical reasons. This is a potential limitation as it may have been expected 
that children receiving inadequate insulin may have even more disordered gastric 
emptying. 
Cases with longstanding T1DM tended to a more pronounced acceleration of gastric 
emptying and a shorter GET1/2. This suggests that there may be a process that occurs as 
the disease progresses that causes gastric emptying to accelerate.  This accelerated 
gastric emptying may in turn contribute to post-prandial hyperglycaemia, which is 
difficult to control even with intensive insulin regimens (103). An awareness of the 
contribution of accelerated gastric emptying to hyperglycaemia may give clinicians 
alternative pathways to pursue to avoid unwanted post-prandial peaks in blood glucose. 
The current study did not include any measures of psychological distress. A clear 
relationship between the mind and gut has been established(142). It has been shown 
that psychological distress can influence the rate of gastric emptying(144). It would 
therefore be interesting when repeating this work in larger groups to include a self-
administered measure of psychological distress such as the Pediatric Quality of Life 
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Inventory (211) or the Problem Areas in Diabetes Survey(212) to examine any potential 
effect psychological factors may have had on gastric emptying. 
The significant fluctuations in blood sugar of the participants was a limitation of this 
study. As stated an insulin clamp was not practical within the resources of the current 
study, however in future studies altering the methodology to include tighter blood 
glucose parameters, perhaps by ensuring stable capillary glucose levels of between 4-
10mmol for a time period before the test may reduce the impact of hyper- and hypo- 
glycaemia on gastric emptying. 
It is also important to note that there is significant inter-individual and intra-individual 
variation in gastric emptying, reflecting the many factors that can influence 
emptying(213). Repeating this study in the same individuals would strengthen the 
conclusions that can be drawn from the results. 
3.5 Conclusion 
The current study showed that in this group of children with T1DM, gastric emptying 
was faster than in cases than controls when eating a standardised pancake meal. This 
finding conflicts with most other research but all studies have been small and few have 
directly measured gastric emptying. 
Further research is needed to establish the physiology of gastric emptying in children 
with T1DM. Examining breath testing in larger groups and repeating the test in the same 
individuals over time may give a clearer picture of the effect that disease progression 
has on gastric emptying. Studying children in euglycaemia and measuring amylin and 
grehlin may illuminate the hormonal mechanisms involved and give better weight to 
pharmacological methods aimed at augmenting blood glucose control. When repeating 
this study in a larger group cases with longstanding and short standing T1DM could be 






 Chapter Four: Gastrointestinal symptoms in children with T1DM 
4.1 Introduction 
Children commonly report gastrointestinal (GI) symptoms, such as abdominal pain (134, 
214). These GI symptoms can impact adversely on the quality of life of a child and their 
family (133). Anecdotally children with T1DM are reported to complain more frequently 
of GI symptoms than their healthy peers. Potential explanations for this could include 
factors such as higher rates of coeliac disease (CD) in T1DM (9), the physiological effects 
of T1DM (215) and that living with a chronic illness may lead to altered perception of 
and increased complaints of pain (216). 
Two reports have assessed GI complaints in children with T1DM compared to healthy 
peers (131, 132). One study evaluating symptoms in adolescents found a high 
prevalence of at least one symptom in cases (75%) and controls (77%): however the 
intensity of symptoms was not ascertained (132). The other report examined the 
prevalence of symptoms in children, but its control group was limited to children of 
hospital staff (131). They found lower rates of symptoms (36.8% cases, 44.9% controls) 
with no statistical difference between the groups. To date there are no published data 
about GI symptoms in New Zealand children with or without diabetes. Consequently, the 
current study aimed to establish the rate and intensity of GI symptoms in a clinic 




Cases were children with T1DM aged 15 years and younger attending the diabetes clinic 
at Christchurch Hospital (the tertiary referral centre for the mid-South Island of New 
Zealand). To establish control data, each case was invited to also give the questionnaire 
to an age matched healthy peer or sibling. Other controls were healthy siblings of 
children admitted to the paediatric wards at Christchurch Hospital and children of staff 
at the Paediatric Department at Christchurch Hospital. 
Children were excluded if they were unable to communicate complaints. They were not 




Caregivers completed a questionnaire regarding GI symptoms (Appendix C). This 10-
question tool was designed to establish the presence and intensity of common 
gastrointestinal symptoms in the preceding 6 months.  The questionnaire was adapted 
to suit a New Zealand audience from a questionnaire designed by Saps et al. (139) to 
study GI symptoms in a community based group of school aged children. This device 
uses questions taken from the Children’s Somatisation Inventory, an extensive well 
validated questionnaire covering many symptom complexes (140). The caregiver was 
asked to include the child when completing the questionnaire.  
Symptoms assessed were: abdominal pain, nausea, vomiting (either an episode or 
persistently), diarrhoea, (either an episode or persistently), constipation, (either an 
episode or persistently), bloating and reflux. “Persistently” was defined as more than 
once in 24 hours for vomiting and greater than a week for constipation and diarrhoea. 
Respondents were asked to choose an answer from a 5-point likert scale (0=not at all, 1 
= a little, 2 = somewhat, 3 = a lot, 4 = a whole lot). A symptom was recorded as “present” 
if the respondent had complained of or experienced the symptom on at least one day in 
the past 6-months. A response of “Severe” was created for each symptom if the response 
on the likert scale was 3 or above. The presence of any of the upper GI symptoms 
(nausea, bloating, vomiting or reflux) was recorded as “Upper GI” present/absent, as 
was the presence of “Lower GI” symptoms (constipation, diarrhoea, persistent 
constipation or persistent diarrhoea). A composite GI symptom score for each individual 
was recorded by summing the likert scale score for each question. 
The questionnaire included questions about demographics, past medical history (PMH) 
of GI disorder, pre-existing medical conditions and family history (FH). In cases the 
result of glycosylated haemoglobin (HbA1c) testing within 3 months of completing the 
questionnaire was obtained from each child’s hospital records, to serve as a proxy 
measure of blood glucose control. 
4.2.3 Statistical analysis 
Results were analysed using Stata/IC 12.1 for Windows (Statacorp, Texas, USA). Data 
were presented as means or proportions as appropriate. Mean values were compared 
using two sample t-tests. Odds ratios (OR), Pearsons chi2 or Fisher’s exact test were 
used to compare dichotomous responses. Regression analysis was performed to 
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evaluate the impact of background factors on the results, logistic for discrete variables, 
linear for continuous. P<0.05 was considered statistically significant. 95% confidence 
intervals were reported where appropriate.  
4.2.4 Ethical approval 
Ethical approval was granted to the study by the Upper South A Regional Ethics 
Committee, Christchurch, New Zealand. Informed consent was attained from the 
guardian and children prior to entry into the study (Appendix B). 
4.3 Results 
4.3.1 Subjects and demographics 
One hundred and fifty cases (88% of eligible population) and 94 controls (38% of 
distributed questionnaires returned) completed the questionnaire. Although cases were 
older than controls, p = 0.01), the two groups were similar for gender and ethnicity 
(Table 4.1). 
Only two cases were excluded due to inability to communicate complaints due to 
developmental delay.  
Table 4.1: Demographic data, all comparisons p >0.05 unless indicated 
 Case Control 
Age (yrs) (mean (95% confidence interval))  10.5 (9.9-11.0) 9.3  (8.7-10.0) (p=0.01) 
Gender 47% – male 47% – male 





Ethnicity –euro 91% 90% 
Ethnicity- nz maori 7% 4% 
Ethnicity - other 2% 5% 
 
4.3.2 Overall GI symptom score 
Children with diabetes were more likely to have a higher mean GI symptom score than 
controls, 4.9(CI 4.0-5.8) v 3.4(CI 2.6-4.2), p = 0.02.  
Eighty percent of controls and 85% of cases reported at least one GI symptom in the 
preceding 6 months, OR 1.5 (CI 0.7 – 3.1) p = 0.3. Adjusting for age, sex, FH or PMH of GI 
condition did not impact on the result (padj = 0.3).  
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4.3.3 Specific GI Symptoms 
The most common symptom reported by children was abdominal pain. Most children 
(73% of cases and 66% of controls) reported at least “a little” abdominal pain in the 
preceding 6 months. (OR 1.4, 95% CI 0.8 – 2.5) (Table 4.2). For each question the mean 
response on the likert scale was higher for cases. Mean likert scores for abdominal pain 
1.3v 1.0 (p= 0.02) and reflux 0.4 v 0.2 (p= 0.01) were the most significantly different 
responses (Table 4.2). Children with T1DM were more likely to complain of the presence 
of any reflux symptoms: OR 2.2 (CI 1.1 – 4.6) (Table 4.2). 



















OR (95% CI) case control 
Abdominal pain 73% 66% 1.4 (0.8-2.5) 1.3 (1.1- 1.5) 1.0 (0.8-1.1)* 
Nausea 43% 36% 0.9 (0.7-2.3) 0.7 (0.5- 0.8) 0.5 (0.4-0.7) 
Vomiting 19% 16% 1.2 (0.6- 2.6) 0.3 (0.2- 0.4) 0.2 (0.1- 0.3) 
Persistent 
vomiting 
9% 6% 1.4 (0.5-4.6) 0.2 (0.1- 0.2) 0.1 (0.0- 0.2) 
Diarrhoea 53% 43% 1.5 (0.9- 2.7) 0.8 (0.7- 1.0) 0.6 (0.4- 0.8) 
Persistent 
diarrhoea 
12% 6% 2.0 (0.7-6.4) 0.2 (0.1- 0.4) 0.1 (0.0- 0.2) 
Constipation 31% 26% 1.3 (0.7- 2.5) 0.4 (0.3- 0.5) 0.4 (0.2- 0.5) 
Persistent 
constipation 
10% 5% 2.0 (0.7-7.1) 0.1 (0.1- 0.2) 0.9 (0.0-0.2) 
Bloating 30% 22% 1.5 (0.8-2.8) 0.5 (0.4- 0.7) 0.3 (0.2- 0.4) 
Reflux 27% 15% 2.2 (1.1- 4.)* 0.4 (0.3- 0.6) 0.2 (0.1-0.3)* 
(OR adjusted for gender, PMH of GI disorder and positive family history of GI disease), * indicates p<0.05 
 
There was an increased proportion of complaints of “severe” abdominal pain in cases, 
17% v 5% of controls; (fisher’s exact p < 0.01), OR 3.6 (1.3 – 12.3).  Very few 
respondents answered 3 or above on the Likert scale for other symptoms; consequently 




Table 4.3: Severe gastrointestinal symptoms in cases and controls 
Symptom 
Likelihood of mean 
response <3 in case, 
OR (95% CI) 
p Case (n) Control (n) 
Abdominal pain 3.6  (1.3  - 12.3) P= 0.01 25 5 
Nausea 2.2  (0.5-12.5) n/s 10 3 
Persistent vomiting  - n/a 2 0 
Vomiting - n/a 2 0 
Diarrhoea 2.2 (0.5-12.5) n/s 10 3 
Persistent diarrhoea 2.2 (0.5-12.5) n/s 10 3 
Constipation 0.9 (0.1-11.4) n/a 3 2 
Persistent constipation - n/a 0 0 
Bloating - n/a 4 0 
Reflux 2.6 (0.5-25.5) n/s 8 2 
 
When examined as symptom complexes, there was no difference in the prevalence of 
upper GI symptoms between cases and controls (61% cases v 49% controls, OR 1.6 (0.9-
2.8)). Similarly there was no difference in the percentage of children who complained of 
lower GI symptoms (56% v 62% OR 1.3 (0.7- 2.2)). 
4.3.4 Pre-existing GI conditions 
Children were not excluded if they had a pre-existing GI issue. Pre-existing conditions 
included: constipation, coeliac disease and abdominal migraine (Table 4.4). Cases were 
more likely to have any pre-existing GI condition, OR 3.0 (95% CI 1.2-8.4, p =0.01). 
Coeliac disease was the most frequently diagnosed condition. 
Table 4.4: Pre-diagnosed gastrointestinal conditions in cases and controls (other was not specified 
by respondent) 
 Case (n=150) Control (n=94) 
None 80% (120) 93% (87) 
Constipation 5% (7) 4% (4) 
Functional Abdominal Pain 2% (3) 1% (1) 
Coeliac disease 7% (10) 0% (0) 
Gastro-oesophageal reflux disease 5% (8) 1% (1) 




4.3.5 Other Pre-existing medical conditions 
Most had no other medical problems (93% of cases and 90% of controls). Seven cases 
(5%) and 9 controls (10%) listed a diagnosis of asthma, 3 cases (2%) and 1 control (1%) 
listed attention deficit hyperactivity disorder as a pre-existing medical condition. 
4.3.6 Family History of GI condition 
Twenty-three controls and 34 cases had a family history of GI issues (no difference 
between the groups, chi2 0.746). Complaints listed included: gastroesophageal reflux, 
irritable bowel syndrome, non-specific abdominal pain, coeliac disease and 
inflammatory bowel disease. 
4.3.7 Factors predictive of gastrointestinal symptoms. 
The presence of T1DM was predictive of a higher GI symptom score (adjusted effect size 
1.60, p 0.01). Higher HbA1c and female gender were both predictive of a higher 
symptom score, whereas ethnicity and age were not. When the model was adjusted for 
gender, the relationship remained significant (Table 4.5). 
Table 4.5: Predictors of gastrointestinal symptom score in NZ children, * indicates p<0.05, 
**adjusted for gender 
Variable Coefficient 
(95% CI of coeffecient) 
Adjusted Coefficient** 
(95% CI of coefficient) 
Diabetes 1.48 (0.24-2.74)* 1.50 (0.27-2.73)* 





-1.24 (-4.46 – 1.97) 
-0.14(-3.39 – 3.09) 
 
Gender -1.85 (-3.06 - -0.65)*  
Age -0.32 (-2.09-0.15)  
 
4.4 Discussion 
This study confirms that complaints of GI symptoms are common in childhood. Overall, 
83% of the total group reported symptoms. The children with T1DM complained of GI 
symptoms as frequently as their peers. However, the intensity of their complaints 
overall was more severe than their peers. In particular, they complained of more severe 
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abdominal pain and reflux symptoms. Factors associated with a higher GI symptom 
score in cases included higher HbA1c and female gender. 
The overall prevalence of GI symptoms in the current report was higher than reported in 
most studies, however no other studies have examined six-month prevalence. A 
community based study found weekly prevalence rates of 45% for any GI complaint 
(133). Most (90%) children complained of abdominal pain during the study period, with 
a weekly prevalence rate of 38%. Weekly rates for other symptoms (nausea 23%, 
diarrhoea 9%, constipation 8% and vomiting 7%) (133) were all lower than the six-
month prevalence reported by the current control group. Higher intensity on a likert 
scale correlated with more absenteeism and increased likelihood of depression and 
anxiety. Further work by the same group found six weekly prevalence rates for the same 
group of symptoms of about 20%, and reported an average intensity of approximately 
1.7 for each of the symptoms, which for the most part is higher than the current study 
(217). 
Other work has focused on complaints of abdominal pain only, with most prevalence 
rates reported at around 50%, again lower than the 73% of cases and 66% of controls in 
the present study. A prospective prevalence study in Australian children presenting to a 
GP practice found 44% had complained of abdominal pain in the last 12 months (218). A 
large World Health Organisation study of the prevalence of somatic pain in adolescents 
(mean age 13.6yrs +-1.7) found that 49.8% complained of stomach-ache monthly or 
more often (134). Girls (59.5%) had a higher prevalence than boys (39.4%) and older 
adolescents (53.4% at 15yrs) complained more than younger children (45.1% at 11yrs). 
Age was not found to be related to symptoms in the current study, however female 
gender was predictive of a higher symptom score.  
Reflux symptoms were not commonly reported overall in the current study. However, 
these symptoms were more common and complaints were more severe in children with 
T1DM than in controls. Although the prevalence of reflux symptoms vary between 
countries and in different age groups, estimates of symptoms in children and 
adolescents range from 2% - 10% (219, 220). Lodefalk et al. (132) found no difference in 
the proportion of young people complaining of reflux symptoms in health or T1DM, but 




Most of the studies investigating the prevalence of pain and other GI disorders in 
childhood have been population-based case finding studies. These studies have used the 
Rome criteria, which were designed as diagnostic criteria for functional gastrointestinal 
disorders (FGID) (221). The current tool was not designed to make a diagnosis of FGID, 
but four children reported a pre-existing GI pain condition. This is much lower than the 
12.5 – 25% previously published for pain predominant conditions (137, 216, 222). It is 
likely there are children in the current study with functional abdominal pain syndromes 
who have not had a formal diagnosis.  
Two studies have investigated complaints of abdominal pain in children with T1DM. A 
Greek study investigated the prevalence of GI symptoms in a consecutive sample of 
children and adolescents attending a diabetes clinic and a well-matched control group of 
siblings of hospitalized children and offspring of hospital staff (131). As in the current 
study, they found no difference between cases and controls (36.8% v 44.9% in controls; 
p 0.17). The overall prevalence rate of any GI symptom complaint was much lower than 
in the current study. The symptoms were assessed by a single researcher administering 
a standard (unidentified, unreferenced) questionnaire. Cases with symptoms did not 
differ significantly from those without. Their results suggest that T1DM had no impact 
on symptom prevalence. However, they did not report the intensity of the symptoms or 
details of the specific symptoms. 
A Swedish study used a postal questionnaire to determine the presence of 13 GI 
symptoms in a population-based group of adolescent cases and controls (132). Their 
findings are similar to the present study with a high prevalence of any GI symptom in 
cases and controls (75% vs 77%; p=ns). They did not find any difference in prevalence 
for any of the individual symptoms, but subgroups were affected by environmental and 
disease specific factors, such as gender and HbA1c, as in the current study.  
The current study has shown that children with T1DM complain of more intense 
symptoms than their peers. The reasons for this may be due to comorbidity, direct 
metabolic effects of hyperglycaemia and psychological reasons.  
Altered gastric emptying is one putative explanation for the increased prevalence of GI 
symptoms in cases. Whilst adult studies (84) have consistently found alterations in 
gastric emptying in diabetes, in children and adolescents the findings have been less 
convincing, with some studies finding delayed gastric emptying (90, 106), others no 
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difference (91, 92) and our own research showing it to be accelerated (Chapter three). 
When present, altered gastric emptying has not consistently been linked to symptoms 
(91, 92). Although altered gastric emptying is a possible explanation for the increased 
complaints of reflux in cases, evidence to support this hypothesis is not convincing. 
In older patients autonomic neuropathy (AN) has been proposed as an explanation for 
more intense and frequent GI complaints (84, 223, 224). In children however, autonomic 
neuropathy is very rare at the onset of diabetes (113) and therefore unlikely to impact 
upon the rate of GI symptoms.  
Coeliac disease is more prevalent in T1DM, with rates somewhere between 2.4%-16.4% 
(225). However, there is a low rate of reported symptoms in undiagnosed children (157, 
167). The standard local practice is to screen at least biannually, so the prevalence of 
undiagnosed CD can be assumed to be low and is unlikely to explain the difference in 
symptom score. 
Perception of sensation from the GI system has been shown to change in both 
hyperglycaemia and hypoglycaemia (102, 208, 215). In the current study higher HbA1c 
was predictive of increased symptom score suggesting on-going persistent 
hyperglycaemia may contribute to symptom prevalence. However, poor control has 
been associated (226, 227), with symptoms of anxiety and depression, and it may be 
that higher HbA1c is a marker of psychological distress rather than the cause of the 
increased symptom complaints. 
The complaints of pain in cases may be associated with the child’s reaction to and 
interpretation of pain. T1DM in children has been shown in a recent meta-analysis to be 
associated with small to moderate levels of psychological distress (226). Functional 
abdominal pain is often worse in children with psychological distress (216). There was 
no measure of psychological upset in the current questionnaire, but it is likely cases did 
have distress, which may affect their interpretation of pain.  
The way parents react to their child’s pain can alter the impairment that results from 
that pain (143). In two large population studies of health related quality of life (HRQL) in 
children with T1DM, children and their parents reported different rates of psychological 
distress (227, 228): the children rated their HRQL higher than their parents reported the 
child’s HRQL. Parent and child were asked to answer the current questionnaire together, 
but as the completion of the questionnaires was not supervised, it is not possible to 
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know how consistently this was done, so the current results may not reflect the true 
symptom intensity experienced by the child. 
A limitation of the current study is the selection of control group children. Siblings of 
children with T1DM are not necessarily a true representation of the normal population. 
The initial intention was to use peers, but recruitment was difficult. Using this group 
does however control for parenting practises and family history. Children recruited from 
the ward were from the same community and geographical area as the cases. 
The current study did not include any measure of psychosocial factors. The participants’ 
addresses were not included in data collection, so there was no means to examine how 
socio economic status may have impacted on children’s reports of GI symptoms. No 
caregivers reported psychological diagnoses, which is surprising given reports of rates 
of up to around 30% for both depression and anxiety in children with T1DM(229, 230)}. 
This is also surprising given the questionnaire was administered after the major 
earthquakes in the Canterbury region in 2010 and 2011 which were associated with an 
increase in anxiety and significant psychological distress(231). Given the strong 
association between psychological distress and GI symptoms including a measure of 
psychological distress such as the Pediatric Quality of Life Inventory(211), or perhaps 
designing the demographic portion of the questionnaire to be more specific about 
psychological co-diagnoses would be useful when repeating the study, to evaluate 
whether there is a link between psychological factors and higher reported rates and 
intensity of symptoms. 
This was a clinic population study, there was an excellent response rate and it was 
representative of the diabetes clinic. A greater number of subjects would have improved 
the power; it is currently powered to detect a difference of 0.7. The size of the study also 
means that the significance of subgroup analysis is limited.  Although this questionnaire 
did have multiple questions, the likelihood of each response is not independent as the 
symptoms occur in complexes and therefore a Bon Ferroni correction would be too 
conservative in this case. While the questionnaire has not been independently validated, 
and therefore results do need to be interpreted with caution, it has been adapted from 
an independently validated questionnaire (139) and the language adapted to the New 




Gastrointestinal complaints were common in this group of children. The children with 
diabetes complained of more intense symptoms than their peers without diabetes. The 
reason for this difference in symptom severity may be related to the pathophysiology of 
T1DM or a psychological response to chronic illness. Further work examining GI 
function and dysfunction in children with T1DM and the psychological and family 






 Chapter Five: Summary and future directions 
5.1 Coeliac disease screening and management benchmark 
There is an increased rate of CD in children with T1DM, with rates of at least 5% 
compared to 1% for CD alone in the NZ population. The two diseases share genetic 
markers and the pathophysiology is almost certainly linked, whether causal or perhaps 
sharing a common pathway. 
There is no clear guidance about who and when to screen for CD in children with T1DM, 
although as time has progressed, it is becoming more accepted that screening is 
appropriate. Evidence is not clear that the combination of the two conditions in 
asymptomatic children does lead to worse outcomes in terms of both growth and poor 
control. The best evidence for the benefit of adopting a GFD is for improving bone health 
and there is emerging evidence that the dual diagnosis is linked to atherosclerotic 
outcomes that may be improved with a GFD. It can also be argued that many children 
report recognise feeling better after commencing the diet, suggesting that they were not 
actually truly asymptomatic. 
This research set out to establish a bench mark of what clinicians in NZ were doing to 
screen and manage children. 
It was well supported and gives a good picture of what 92% of the clinicians caring for 
children with T1DM were doing at that point in time.  
Although the majority of respondents did screen at diagnosis, approximately a third did 
not. Those that did not screen used symptoms, poor growth and poor control as triggers, 
as well as the recognition that family history put children at risk. This approach has the 
potential risk of missing children as much of the body of evidence suggests that these 
presenting features are not commonly found in children with CD. All but two 
respondents suggested that they would recommend to commence a GFD once CD was 
diagnosed. Commencement of GFD in this setting, regardless of the presence of 
symptoms, is currently the standard of care. However, clearly, as acknowledged by the 
responding physicians, this does place an additional burden upon these children and 
their families. Although there is no definitive data at present, there is a very interesting 
randomised control trial under way that may well provide some guidance to whether or 
not this is indeed best practice in children with T1DM (201). 
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5.2 Gastric emptying rates in children with T1DM 
Most methods to measure GE are invasive (i.e. scintigraphy) or are only indirectly 
related to gastric emptying (i.e. electrogastrography). Delayed gastric emptying has 
repeatedly been shown in adults with T1DM.  GE in children with T1DM is far less well 
documented. Several small studies exist using various methodologies (88-90) but the 
results are conflicting, some demonstrate delayed gastric emptying (93), no change in 
two (91, 92) and one study showed faster gastric emptying (95).   
This was a pilot study to determine if children with T1DM have slower GE compared to 
non-diabetic controls. Gastric emptying was measured using Carbon 13 (C13) breath 
testing, a non-invasive, very low risk procedure that accurately correlates with GE time. 
Nineteen cases and 15 age and sex matched controls underwent testing.  In conflict with 
the original hypothesis the mean GEC in cases was higher than in controls, indicating a 
shorter gastric emptying time (3.19 (2.97 – 3.41) vs 2.90 (2.74 - 3.10), p = 0.03). Mean 
GET1/2 was not different between the two groups (cases 99 (68 - 128) mins vs 103 (88-
118) mins, p = 0.8).  
Secondary analysis suggested that there was a connection between the duration and a 
more pronounced increase in the speed of gastric emptying but numbers were small and 
the result didn’t meet statistical significance. There was no correlation with Hba1c, BMI-
z score, symptom score or age. 
This finding was contrary to the original hypothesis, but there are several mechanisms, 
which could explain the finding. GE is difficult to measure and many factors influence the 
rate. One major drawback of the current study is that the children were not clamped and 
their blood glucose did not remain within the physiological range. However the children 
with hypoglycaemia which could potentially have caused an acceleration of GE were 
excluded and many of the children were in fact hyperglycaemic especially initially, 
which would have been expected to delay gastric emptying, rather than cause the 
accelerated GE seen. 
 The literature does offer potential explanations for accelerated gastric emptying such as 
alterations in gastric hormones such as amylin and ghrelin, which may mean that in 
T1DM the normal slowing of gastric emptying in response to a meal is disrupted. This 
acceleration may contribute to the often observed post prandial hyperglycaemia, which 
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is an important target when looking to modify blood glucose control and achieve better 
long term outcomes for children with T1DM. 
5.3 Gastrointestinal symptoms in children with T1DM 
Complaints of gastrointestinal symptoms are common in the paediatric age group. 
Children with T1DM are reported to have more gastrointestinal symptoms than their 
healthy peers, however evidence demonstrating this is limited. The evidence that is 
available suggests that rates of complaints are the same in children with and without 
T1DM. No attempt had been made to estimate the intensity of symptom complaints in 
children with T1DM. We aimed to document the rate and intensity of gastrointestinal 
symptoms reported in a clinic population of children with T1DM compared to an age 
matched group of healthy children. 
A large group of children, 88% of the eligible clinic population, completed the 
questionnaire. As in previous work both groups had similar rates of any GI symptoms 
(80% of controls v 85% cases OR 1.5 (0.7-3.1)). The proportion of children complaining 
was much higher than one study (approximately 40%)(131), but was concordant with a 
larger group of adolescents (around 70%)(132).  Methodological differences and the 
way symptoms were measured partially explains the differences in symptom rate. 
Children with T1DM had higher mean scores for abdominal pain (1.3 v 1.0, p = 0.02) and 
reflux (0.4 v 0.20, p = 0.02). The overall mean score was also higher in cases (4.9 v 3.4, p 
= 0.02) indicating the intensity of their complaints was higher than healthy controls.  
There are many plausible mechanisms, both physical and psychological that suggest 
children with T1DM would complain of more intense symptoms than healthy controls. 
Certain pathologies are found more commonly in children with T1DM, such as gastric 
emptying differences, higher rates of subclinical CD, or direct effects of hyperglycaemia. 
A higher HbA1c was associated with a greater symptom score in the current study. 
Children with T1DM were more likely to have a PMH of a GI condition, such as CD, 
although adjusting for this did not alter the significance of the result. 
It is also likely that children with T1DM and their parents react differently to pain than 
children without a chronic illness. The gastrointestinal system and central nervous 
system are closely related; psychological stress exacerbates and magnifies the bodies’ 
response to stimuli that may otherwise be interpreted as innocuous. T1DM is associated 
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with higher levels of psychological distress; a chronic disease such as T1DM is a burden 
and will impact on how children interpret messages from their body.  
5.4 Future Directions 
5.4.1 Coeliac Disease in T1DM 
The prospective randomised controlled trial currently underway will be very welcome 
as it will hopefully give better information as to what to do in the vexing situation of an 
asymptomatic child with T1DM (201). It aims to document bone density, hypoglycaemia 
and HbA1c as well as quality of life, with a proposed follow up of one year.  This is a 
short time period as many of the potential drawbacks of the combination diagnosis will 
take many years to be apparent, particularly when considering bone health and 
microvascular complications of T1DM. A study to follow a cohort of children randomised 
to GFD/non GFD would be ideal, although given there is potential harm of not adopting a 
GFD, ethical and design strategies would need to be carefully thought out. 
There is potential for such a study to shed light on causal mechanisms of CD. The 
children could have their bowel flora measured and this could be contrasted and 
compared with a group of non-sero positive children. Prospectively changes to the 
microbiota on the GFD could be examined. 
One way to gather data about potential mechanisms would be to retrospectively 
examine the clinic population in Christchurch over the last 10 years, when it has been 
customary to measure coeliac serology at least once, but more typically every other year 
in the diabetes clinic population. This could give good prevalence data and can add to 
the information regarding growth and HbA1c. Children and adolescents could be 
recruited for further study, bone density could be measured and information gathered 
regarding T1DM complications, much of this data would be pre-existing. Quality of life 
and a measure of GI symptoms could also be included.   
5.4.2 Gastric emptying 
As the current work was a pilot it will be important to repeat the study in a larger group 
of cases and controls. In order to demonstrate more clearly the physiology of gastric 
emptying in T1DM intra-individual variation is perhaps more important than inter-
individual variation, so to further explore the finding that duration may be linked to 
rapid gastric emptying repeating the study in the same individual over a series of years 
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would be very interesting. This could be coupled with prospective evaluation of 
symptoms, growth parameters and blood glucose control.  
To add further weight to the robustness of the measurement of gastric emptying, EEG 
could be used as another supplementary measure and the results correlated. 
If funding and ethics could be obtained then studying the children on an insulin clamp 
and with measurement of gastric hormones would give information about potential 
hormonal causal mechanisms. Collecting data on coeliac sero-positivity and subsequent 
development of the disease may be interesting, but numbers would have to be very large 
to gather meaningful data. 
5.4.3 GI symptoms in children with T1DM 
This novel finding of more intense symptoms in children with T1DM poses many 
questions that could be explored in future work. As this study was purely observational 
it does not offer explanations as to what drives the increase in intensity of symptoms. 
Future investigation could look to examine the pathophysiological differences in the gut 
in T1DM, hormonal changes and of course gastric emptying.  
Studies may be able to focus on some of the physical causes such as correlating gastric 
emptying parameters in a much larger group of children with intensity of symptoms. 
Similarly measurement of gastric or systemic hormones postulated to be involved may 
be illustrative.  
Other areas of focus could be the psychological impact of T1DM and how this impacts on 
children and their quality of life. Work could focus on better measurement of 
psychological parameters; perhaps it could correlate measures of quality of life or 
psychological distress with symptoms.  
In addition it could be useful to explore more information about the cases, particularly 
age, although it was not obviously associated with intensity in this study a larger group 
of adolescents may be worth studying, and including data about duration of T1DM to see 
if this too impacts on results. 
A very interesting field that is becoming the focus of more work is that of the gut flora. 
Stool samples could be analysed between cases and controls to see if there is a particular 
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flora that is linked with symptoms. This could lead to interventional studies, such as 
investigating whether treatment with a probiotic changes the intensity of symptoms. 
5.5 Final Thoughts 
This thesis examines three relatively diverse aspects of gastrointestinal manifestations 
of T1DM. However all three aspects, CD, gastric emptying and the experience of GI 
symptoms are related. 
Coeliac disease can cause significant disease and symptoms. Living with two chronic 
illnesses can be burdensome and increase a child and their family’s level of 
psychological distress, especially if their clinicians cannot offer them good advice on the 
best way to proceed with management of the dual diagnosis.  
Gastric emptying has important implications for the control of T1DM. Alterations in 
gastric emptying may cause symptoms such as nausea and reflux. Recognition of altered 
gastric emptying may give the clinician and families another way to improve control of 
T1DM. 
Although all children complain of symptoms, those complaints are more intense in 
children with T1DM. Whilst it is likely there are disease-related pathologies, such as CD 
and altered gastric emptying contributing to this, the child and their family’s level of 
stress and how they perceive their quality of life may well modify the level of distress 
caused by GI symptoms. Perceiving GI symptoms and dealing with these complaints is 
likely to increase the burden they perceive from their illness. 
Poor control of T1DM is linked with increased GI symptoms and alterations in gastric 
emptying. CD and altered gastric emptying both potentially contribute to 
hyperglycaemia. The current study emphasises the fact that T1DM affects all body 
systems. Research and clinicians should ensure their focus is not only on blood glucose 
control. By recognising and managing the important GI manifestations, the burden for a 
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Appendix A – Coeliac Survey 
Page One 
Thank you for taking part in the survey. There are 3 pages with 24 
questions. It should take about 5 minutes to answer. 
If the answer is multi-choice please place a y beside the most 
appropriate answer 
 
The first two pages are designed to discover current practises in New 
Zealand regarding Coeliac disease in T1DM. 
 
1.) Please enter your contact details, responses will be confidential 
First Name: ___________________________________________ 
Last Name: ____________________________________________ 
City: ____________________________________________ 
Email Address: ____________________________________________ 
At which DHB(s) do you currently care for children with type one diabetes?: 
____________________________________________ 
 
2.) Which best describes you?  
[ ] Paediatric endocrinologist 
[ ] General paediatrician 
[ ] Adult physician 
[ ] Other 
 




4.) In your diabetes clinics how many children with T1DM have been 





5.) In your diabetes clinics do you have a formal protocol for 
screening and managing coeliac disease? (If you work at more than 
one hospital, please answer for the main hospital you work at) 
( ) Yes 
( ) No 
 






7.) Do you screen children for coeliac disease at diagnosis of T1DM? 
( ) Yes, please go to question 8 
( ) No, please go to question 11 
 
8.) If you do screen for coeliac disease at diagnosis of T1DM, what do 
you use? (you may mark more than one answer) 
[ ] Tissue transglutaminase (TTG) 
[ ] Endomysial autoantibodies (EMA) 
[ ] Antigliadin antibodies 
[ ] Deaminated gliadin 
[ ] HLA typing 
[ ] Iron levels 
[ ] Serum IgA 




9.) If you answered yes to question 7, how often do you subsequently 




10.) If you answered yes to question 7, what do you use to screen for 
coeliac disease in T1DM subsequently? (you may mark more than one 
answer) After you answer this please go straight to question 13 
 
[ ] Tissue transglutaminase (TTG) 
[ ] Endomysial autoantibody (EMA) 
[ ] Antigliadin antibody 
[ ] HLA typing 
[ ] Deaminated gliadin 
[ ] Iron levels 
[ ] Serum IgA 
[ ] Other, please specify 
 
11.) If you answered no to question 7, what is your trigger if any, for 
screening for coeliac disease? (you may mark more than one answer) 
[ ] Diarrhoea 
[ ] Anaemia 
[ ] Poor growth 
[ ] Erratic blood sugar control 
[ ] Recurrent hypoglycaemia 
[ ] Family history 
[ ] Other, please specify: 





12.) If you answered no to question 7, but you do screen for coeliac 
disease in T1DM, what do you use? (you may mark more than one 
answer) After you answer this please go straight to question 13 
[ ] Tissue transglutaminase (TTG) 
[ ] Endomysial autoantibody (EMA) 
[ ] Antigliadin antibody 
[ ] HLA typing 
[ ] Deaminated gliadin 
[ ] Iron levels 
[ ] Serum IgA 
[ ] Other, please specify 
 
13.) If screening suggests possible coeliac disease, what is your next 
step? (you may mark more than one answer) 
[ ] Refer for endoscopy 
[ ] Commence a gluten free diet without endoscopy 
[ ] Repeat bloods 







14.) With reference to screening for coeliac disease in T1DM, what is 







15.) What is the criteria in your population group for commencing a 
gluten free diet? (please pick one answer) 
( ) Biopsy proven coeliac disease 
( ) Positive coeliac serology 
( ) Symptoms suggestive of coeliac disease 
( ) Other, please specify 
 
16.) What is your standard approach with children who have T1DM 
and symptom free coeliac disease? 
 
   
 
17.) What is your standard approach with children who decline to 









The next section is designed to assess the level of understanding 
surrounding coeliac disease in type one diabetes. 
 
18.) What do you understand to be the prevalence of coeliac disease 




19.) What do you think is the most common presentation of coeliac 
disease in T1DM? (please pick one answer) 
( ) Asymptomatic - discovered incidentally/on screening 
( ) Erratic blood sugar control 
( ) Poor growth 
( ) Anaemia 
( ) Diarrhoea 
( ) Abdominal pain 
( ) Frequent hypoglycaemia 
( ) Other, please specify: 
 
20.) What do you think is the most sensitive test to screen for coeliac 
disease?  
[ ] Tissue transglutaminase (TTG) 
[ ] Endomysial autoantibody (EMA) 
[ ] Antigliadin antibody 
[ ] HLA typing 
[ ] Deaminated gliadin 
[ ] Iron levels 
[ ] Serum IgA 




21.) What do you think is the most specific test to screen for coeliac 
disease?  
[ ] Tissue transglutaminase (TTG) 
[ ] Endomysial autoantibody (EMA) 
[ ] Antigliadin antibody 
[ ] HLA typing 
[ ] Deaminated gliadin 
[ ] Iron levels 
[ ] Serum IgA 
[ ] Other, please specify 
 
22.) What is the best test to diagnose coeliac disease once it is 
suggested by screening? 
____________________________________________  
 
23.) Are you aware of the current APEG (Australian Paediatric 
Endocrine Group) guidelines regarding coeliac disease in T1DM? 
[ ] Yes 
[ ] No 
 
24.) Please feel free to add any additional comments regarding coeliac 






Thank you very much for taking the time to complete the survey. I will 























Upper South A Regional Ethics Committee 
c/- Ministry of Health 
Montgomery Watson Building 
6 Hazeldean Road 
Christchurch 
Phone: (03) 974 2304 





8 August 2011 
 
Associate Professor Andrew Day 
Department of Paediatrics 
University of Otago 




Dear Associate Professor Day 
 
 
Ethics ref: URA/10/07/051  (please quote in all correspondence) 
Study title: Gastrointestinal manifestations of type one diabetes in children 
Investigators:  A/Prof A Day, Dr J Porter 
 
Thank you for the progress report for the above study, which was considered by the 
Chairperson of the Upper South A Regional Ethics Committee. 
 
Ethical approval is confirmed for a further 12 months from the report due date. We look 
forward to receiving another report from you in September 2012. 
 












Health and Disability Ethics Committees 
1 the Terrace 




 0800 4 ETHICS 
hdecs@moh.govt.nz 
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21 December 2012 
 
 
Professor Andrew Day  
Paediatric Department 
University of Otago,Christchurch 




Dear Professor Day 
 
 
Re: Ethics ref: URA/10/07/051/AM01 
 Study title: Gastrointestinal manifestations of type one diabetes in children 
 
 
This letter is to confirm receipt of the annual progress report for this study, submitted on 
20 December 2012. HDEC approval for the study is re-confirmed for the period 30 
September 2012 to 30 September 2013. 
 
The Southern Health and Disability Ethics Committee will be in contact with you within 15 
days of this date if it requires further information on any matter relating to this annual 
progress report, or if it wishes to reconsider its approval for the study.  In the absence of 
such contact you should assume that the annual progress report has been accepted and 
approved without comment.  No separate letter will be sent confirming this. 
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